Clinical Pharmacy 1993: Vol 12 Index

11 Pages·1993·3.2 MB·English

Index to Volume 12
The index to Volume 12 is composed of three parts: a subject Clinical Pharmacy, as well as selected letters and news reports.
index, an author index, and an advertising index. The subject index also notes all regular columns and, under the
The subject index is made up mainly of terms constructed by respective column headings, the titles of items in the “News,”
International Pharmaceutical Abstracts. The IPA index is an alpha- “Therapy Consultation,” “Letters,” “Editorials,” and “Book Re-
betical, open-ended, controlled-vocabulary index that makes use views” sections. The subject index also contains, under the head-
of standardized headings. (The primary index terms for each ing “Correction Notices,” the title and issue of publication of
article are listed routinely in Clinical Pharmacy as “index terms” items for which corrections were printed, as well as the page
after abstracts.) IPA covers all authored papers and editorials in numbers on which the corrections appear.
Issue Pages Issue Pages
January 1-84 July 469-548
February 85-164 August 549-628
March 165-244 September 629-708
April 245-324 October 709-788
May 325-388 November 789-868
June 389-468 December 869-948
Subject Index
A American Journal of Hospital Pharmacy; journals; Antibiotics
merging, Clinical Pharmacy, 526, 923 aztreonam and clindamycin; or metronidazole, colo-
American Society of Hospital Pharmacists rectal surgery, prophylaxis, 399
Acecainide; blood levels; fluorescence polarization journals; AJHP, Clinical Pharmacy, merging, 526, 923 clindamycin and aztreonam; colorectal surgery, pro-
methods, 49 protocols; antimicrobial prophylaxis, colorectal sur- phylaxis, 399
N-Acetyl-t-tyrosine; excretion; excretion, infants, par- gery, 399 cystic fibrosis; therapy, review, 657
enteral nutrition, 606 Amino acids; dietary supplements; athletes, ergogenic shock; septic, therapy, review, 829
N-Acetylprocainamide, see Acecainide effects, 900 vancomycin; pharmacokinetics, geriatrics, 481; phar-
Acquired immunodeficiency syndrome Aminoglycosides macokinetics, prediction, 909
atovaquone; pneumonia therapy, FDA approvals, 175 gentamicin; pharmacokinetics, prediction, vancomy- vancomycin hydrochloride; dosage, calculations,
didanosine, comparison, zalcitabine; therapy, effica- cin pharmacokinetics, 909 computers, 126; pharmacokinetics, dosage, hema-
cy, NIAID clinical studies, 391 gentamicin sulfate; body distribution, septic shock, tologic malignancy, 515
stavudine; therapy, parallel track policy, FDA ap- 131; pharmacokinetics, term newborn twins, 615 Antibodies; monoclonal; graft vs. host disease, prophy-
provals, 7 tobramycin; pharmacokinetics, prediction, vancomy- laxis, transplantation, 736; septic shock therapy, re-
unapproved drugs; imports, AIDS buyers’ clubs, FDA cin pharmacokinetics, 909 view, 829
regulations, 632 tobramycin sulfate; body distribution, septic shock, Anticoagulants
zalcitabine, comparison, didanosine; therapy, effica- 131 enoxaparin; FDA approvals, 471
cy, NIAID clinical studies, 391 Amiodarone glomerulonephritis; membranoproliferative, therapy,
Acyclovir; chickenpox; rational therapy, AAP recom- photosensitivity; toxicity, review, 580 review, 429
mendations, 175 toxicity; thyroid dysfunction, therapy, 774 heparin; dosage estimation, pharmacokinetic models,
Addicts; opiates; levomethadyl maintenance, narcotic Amlodipine besylate; marketing; FDA approvals, 93 597; low molecular weight, cerebrovascular disor-
treatment programs, 797 Amoxicillin; bismuth and metronidazole; peptic ulcer ders therapy, review, 359; myocardial infarction
Administration therapy, H. pylori, review, 34 therapy, 197
hospital pharmacy; NSAIDs, DUE criteria, 780 Analgesics and antipyretics heparins; low-molecular-weight vs. unfractionated,
Food and Drug Administration; accelerated drug ap- fentanyl; transdermal pain therapy, 718 thrombophlebitis, 892
provals, final regulations, 253 meperidine hydrochloride; patient-controlled analge- ticlopidine hydrochloride; toxicity, cholestasis, 398
Adrenergic agents, see Sympathomimetic agents sia, DUE criteria, 150 warfarin; atrial fibrillation, atrial flutter therapy, 721;
Adverse reactions, see Drugs, adverse reactions morphine; fentanyl replacement pain therapy, 718 myocardial infarction therapy, 197
Advertising; industry, pharmaceutical; accelerated morphine sulfate; patient-controlled analgesia, DUE Anticonvulsants
drug approvals, FDA regulations, 253 criteria, 150 diazepam; seizures, therapy, ondansetron adverse re-
Advertising Index, 84, 164, 244, 324, 388, 468, 548, 628, premenstrual syndrome; therapy, headache, 181 actions, 613
708, 788, 868, 935 Anaphylaxis; replacement solutions; review, 335 felbamate; marketing, FDA approvals, 713
AIDS, see Acquired immunodeficiency syndrome Anemia phenytoin; unbound, blood levels prediction, equa-
Age epoetin alfa; therapy, DUE criteria, 925 tions, 913
patients; effects, mexiletine pharmacokinetics, 768 temafloxacin hydrochloride; hemolytic, adverse reac- valproic acid; toxicity, pancreatitis, review, 440
pediatrics; N-acetyl-t-tyrosine, excretion, infants, nu- tions, 380 Antidepressants
trition, 606 Anesthetics premenstrual syndrome; therapy, psychological
Agency for Health Care Policy and Research; grants; midazolam hydrochloride; follicular fluid levels, in symptoms, 181
pharmacists’ role, health care, 474 vitro fertilization, 770 sertraline hydrochloride; interactions, tranylcypro-
Agranulocytosis; sargramostim; therapy, sulfasalazine propofol; toxicity, aggressive sex behavior, 449 mine, serotonergic syndrome, 222
toxicity, 179 Anesthetics, local; benzocaine; allergies, photosensitivi- tranylcypromine sulfate; interactions, sertraline, sero-
Albumin human; effects; serum protein levels, paren- ty, review, 580 tonergic syndrome, 222
teral nutrition, 377 Angina pectoris; amlodipine besylate; therapy, FDA Antiemetics; ondansetron hydrochloride; adverse reac-
Albumin; replacement solutions; selection, clinical approvals, 93 tions, seizures, 613
studies, review, 335 Angiotensin-converting-enzyme inhibitors Antifungals; itraconazole; FDA approvals, 6
Aldesleukin; use; evaluation, criteria, 853 hypertension; systolic, therapy, geriatrics, review, 347 Antihistamines; loratadine; FDA approvals, 474
Allergies proteinuria; therapy, nephrotic syndrome, review, Anti-infective agents
drugs; photosensitivity, review, 580 429 atovaquone; pneumonia therapy, FDA approvals, 175
temafloxacin hydrochloride; hemolytic anemia, 380 Antacids; labeling; nonprescription drugs, FDA regula- metronidazole; and aztreonam, colorectal surgery,
Alprazolam; premenstrual syndrome; therapy, psycho- tions, 800 prophylaxis, 399; peptic ulcers, H. pylori, combined
Alzlohgeiicmale r’ssy mpdtiosmesa,se ; 181t acrine hydrochloride; therapy, Antfhorxaidcey cltihnereasp;y , t5ox6i0c ity; extravasation, dimethyl sul- tichietry,a p8y8,1 review, 34; diarrhea, therapy, cefixime tox-
FDA approvals, 873 Antiarrhythmic drugs, see Cardiac drugs pentamidine; toxicity, pancreatitis, review, 440
American Academy of Pediatrics Antidiarrhea agents; labeling; nonprescription drugs, peritonitis; therapy, effects, «,-acid glycoprotein con-
acyclovir; chickenpox therapy, AAP recommenda- FDA regulations, 800 centrations, 602
tions, 175 Antiemetics; labeling; nonprescription drugs, FDA reg- Anti-inflammatory agents
chloral hydrate; pediatric use, recommendations, 876 ulations, 800 methotrexate; asthma therapy, overview, 762
Antianemia drugs; epoetin alfa; DUE criteria, 925 nonsteroidal; DUE criteria, 780; polymyalgia rheu-
Vol 12 Dec 1993 Clinical Pharmacy 937
Annual Index
matica therapy, review, 571; proteinuria therapy, Bipolar disorder; lithium; therapy, DUE criteria, 617 Carbohydrates; nutrition; support, respiratory tract dis-
nephrotic syndrome, review, 429 Bismuth; ulcers; peptic, combined therapy, H. pylori, eases, 276
sulindac; toxicity, pancreatitis, review, 440 review, 34 Carcinogenicity; chloral hydrate; toxicity, lack, 876
Antilipemic agents; nephrotic syndrome; complica- Blastomycosis; itraconazole; therapy, FDA approvals, 6 Cardiac drugs
tions, therapy, review, 429 Blood levels amiodarone; photosensitivity, toxicity, review, 580;
Antimanic agents; lithium; DUE criteria, 617 acecainide; fluorescence polarization methods, 49 toxicity, thyroid dysfunction, therapy, 774
Antineoplastic agents N-acetyl-.-tyrosine; excretion, infants, parenteral nu- amlodipine besylate; FDA approvals, 93
aldesleukin; DUE criteria, 853 trition, 606 antiarrhythmic agents; atrial fibrillation, atrial flutter
asparaginase; toxicity, pancreatitis, review, 440 a,-acid glycoproteins; and dialysate, effects, peritoni- therapy, 721
cladribine; FDA approvals, 391; leukemia therapy, re- tis, 602 digoxin; atrial fibrillation, atrial flutter therapy, 721
view, 805 clonidine hydrochloride; infant, maternal consump- flosequinan; high dose, toxicity, clinical studies, 474;
finasteride; prostatic hypertrophy therapy, review, 15 tion, lactation, 178 product withdrawal, toxicity, 713
leucovorin calcium, comparison, levoleucovorin cal- gentamicin; pharmacokinetics, term newborn twins, isosorbide dinitrate; systolic hypertension therapy,
cium; equivalency, i.v. vs. oral, availability, 293 615 geriatrics, review, 347
levoleucovorin calcium, comparison, leucovorin cal- lidocaine hydrochloride; monitoring, pharmacists’ lidocaine hydrochloride; pharmacokinetics monitor-
cium; equivalency, i.v. vs. oral, availability, 293 role, 527 ing, pharmacists’ role, 527
mercaptopurine; toxicity, pancreatitis, review, 440 N-5-methyltetrahydrofolate; leucovorin—levoleuco- magnesium; myocardial infarction therapy, mecha-
nephrotic syndrome; therapy, review, 429 vorin generic equivalency, 293 nism of action, review, 588
paclitaxel; refractory ovarian neoplasms therapy, re- midazolam hydrochloride; follicular fluid, in vitro mexiletine; pharmacokinetics, middle-aged and eld-
view, 401 fertilization, 770 erly patients, 768
teniposide; FDA approvals, 6 phenytoin; prediction, equations, unbound concen- nifedipine; toxicity, bezoars, sustained-action tablets,
toxicity; anemia, epoetin alfa therapy, DUE criteria, tration, 913 849
925 procainamide; fluorescence polarization methods, 49 procainamide; blood levels, fluorescence polarization
Antithymocyte globulin; graft vs. host disease; prophy- quinidine; binding, effects, ultrafiltration, 917; fluo- methods, 49
laxis, bone marrow transplantation, 736 rescence poiarization vs. EMIT, 49 procainamide hydrochloride; side effects, lack, preg-
Antithyroid drugs tetrahydrofolic acid; leucovorin-levoleucovorin ge- nancy, 58
hyperthyroidism; therapy, 774 neric equivalency, 293 quinidine; binding, blood levels, effects, ultrafiltra-
propylthiouracil; hyperthyroidism therapy, 774 vancomycin; dosage calculations, computers, 126; tion, temperature, 917; blood levels, fluorescence
Antituberculars; resistance; M. tuberculosis, health pro- pharmacokinetics, geriatrics, 481 polarization vs. EMIT, 49
fessions, surveillance programs, 167 Blood; resuscitation; clinical studies, review, 335 sotalol hydrochloride; arrhythmia therapy, review,
Antivirals Bone neoplasms; strontium chloride Sr 89; pain thera- 883; FDA approvals, 176
acyclovir; chickenpox therapy, AAP recommenda- py, FDA approvals, 632 Carnitine; dietary supplements; athletes, ergogenic ef-
tions, 175 Book Reviews, 76, 240, 323, 387, 467, 627, 704, 787, 864, fects, 900
didanosine; toxicity, pancreatitis, review, 440 933 Cathartics and laxatives
didanosine, comparison, zalcitabine; AIDS therapy, Applied Pharmacokinetics: Principles of Therapeutic Drug glycern; enemas vs. suppositories, neonates, 846
efficacy, NIAID clinical studies, 391 Monitoring, Third Edition, 323 labeling; nonprescription drugs, FDA regulations, 800
ribavirin; bronchiolitis therapy, pediatrics, review, 95 Cancer: Principles and Practice of Oncology, 4th Edition, Catheters; intravenous; pressure, extravasation predic-
stavudine; AIDS therapy, parallel track policy, FDA 864 tion, infants, 216
approvals, 7 The Chemotherapy Source Book, 240 Cefepime; pharmacokinetics; cholecystectomy, acute
zalcitabine, comparison, didanosine; AIDS therapy, Clinical Epidemiology: A Basic Science for Clinical Medi cholecystitis, 134
efficacy, NIAID clinical studies, 391 cine, Second Edition, 866 Cefixime; toxicity; diarrhea, metronidazole therapy, 881
Anxiolytics, sedatives and hypnotics Clinical Pharmacokinetics Pocket Reference, 933 Centocor; product withdrawal; nebacumab, 254
chloral hydrate; pediatric use, AAP recommenda- Clinical Pharmacology: Basic Principles in Therapeutics, Central nervous system stimulants; tacrine hydrochlo-
tions, 876 Third Edition, 76 ride; marketing, FDA approvals, 873
labeling; nonprescription drugs, FDA regulations, 800 Clinical Pharmacy and Therapeutics, Fifth Edition, 704 Cephalosporins
zolpidem tartrate; insomnia therapy, review, 814 Drugs in Anaesthetic Practice, Seventh Edition, 241 cefepime; pharmacokinetics, cholecystectomy, acute
Arrhythmia; sotalol hydrochloride; therapy, review, Drug Susceptibility in the Chemotherapy of Mycobacterial cholecystitis, 134
883; ventricular, therapy, FDA approvals, 176 Infections, 82. cefixime; toxicity, diarrhea, metronidazole therapy,
Arteritis; relationship; giant cell, polymyalgia rheumat- Essentials of Basic Science: Pharmacology, 704 881
ica therapy, 571 Geriatric Nutrition: The Health Professional's Handbook, Cerebrovascular disorders
Arthritis; anti-inflammatory agents; nonsteroidal, ther- 933 therapy; review, 359
apy, DUE criteria, 780 Handbook of Cancer Chemotherapy, Third Edition, 241 ticlopidine; therapy, DUE criteria, 64
Asparaginase; toxicity; pancreatitis, review, 440 Handbook of Clinical Drug Data, Seventh Edition, 706 Certification; specialties; pharmacists, pharmaceutical
Aspergillosis; prednisone; allergic bronchopulmonary, Handbook of Medical Toxicology, 627 care, ASHP, 923
therapy, review, 24 Handbook of Psychotropic Drugs, 242 Chickenpox; acyclovir; rational therapy, AAP recom-
Asthma; methotrexate; therapy, overview, 762 Management of HIV Infection in Infants and Children, 787 mendations, 175
Athletes; dietary supplements; ergogenic effects, 900 Martindale: The Extra Pharmacopoeia, 30th Edition, 934 Chloral hydrate; pediatrics; AAP recommendations,
Atovaquone Patient Recruitment in Clinical Trials, 387 876
marketing; FDA approvals, 175 Progress in Basic and Clinical Pharmacology, Vol. 9 Cholecystitis; cefepime; pharmacokinetics, cholecystec-
pneumonia; P. carinii, therapy, review, 563 Effects of Drugs on Human Functioning, 867 tomy, 134
Atrial fibrillation; therapy; review, 721 Tardive Dyskinesia, 467 Cholestasis; ticlopidine hydrochloride; toxicity, 398
Atrial flutter; therapy; review, 721 Textbook of Clinical Neuropharmacology and Therapeutics, Ciprofloxacin; use; evaluation, criteria, 226
Availability, drugs, see Drugs, availability Second Edition, 707 Cisapride; marketing; FDA approvals, 876
Azathioprine; toxicity; pancreatitis, review, 440 Books Received, 84, 164, 324, 388, 468, 548, 627, 707, 787, Cladribine
Aztreonam; and clindamycin or metronidazole; colorec- 867, 935 leukemia; therapy, review, 805
tal surgery, prophylaxis, ASHP protocols, 399 Boots Pharmaceuticals; flosequinan; product with- marketing; FDA approvals, 391
drawal, toxicity, 713 Clearance, see Excretion
Bromocriptine; premenstrual syndrome; therapy, mas- Clindamycin; and aztreonam; colorectal surgery, pro-
todynia, 181 phylaxis, ASHP protocols, 399
Bronchiolitis; therapy; pediatrics, review, 95 Clinical Pharmacy
acknowledgment to reviewers—October 1, 1992, to
Bacstuerrgiearly , ipnrfoecpthiyolnasx;i s,a nAtiS-HinPf ecptriovteo coalgse, nt3s9;9 colorectal Cc jouSrenpaltse;m bmeerr g3i0n,g 19A9J3H, P,92 35 26, 923
BCG vaccines; immunization; tuberculosis, health pro- instructions for submitting computer disks with re-
fessions, surveillance programs, 167 vised manuscripts, 63, 535
Benzocaine; photosensitivity; adverse reactions, re- Calcium antagonists procedure for submission of manuscripts to journals
view, 580 atrial fibrillation; therapy, and atrial flutter, 721 published by the American Society of Hospital
Benzodiazepine antagonists; flumazenil; DUE criteria, felodipine; hypertension therapy, review, 261 Pharmacists, 61, 533
536; overdose, therapy, review, 641; rational therapy, hypertension; systolic, therapy, geriatrics, review, 347 Clinical studies
overdose, overview, 691; respiratory depression ther- isradipine; hypertension therapy, review, 261 nebacumab; marketing. withdrawal, toxicity, 254
apy, benzodiazepine toxicity, 483 Calcium regulators didanosine, comparison, zalcitabine; AIDS therapy,
Benzodiazepines gallium nitrate; hypercalcemia therapy, malignancy- efficacy, 391
overdose; toxicity, flumazenil therapy, DUE criteria, induced, review, 117 drugs; alerts, NIH guidelines, news media, 637
536 pamidronate disodium; hypercalcemia therapy, flosequinan; high dose, toxicity, mortality, 474
toxicity; overdose, flumazenil therapy, overview, 691; malignancy-induced, review, 117 replacement solutions; resuscitation, review, 415; re-
overdose, flumazenil therapy, review, 641; respira- Calculations suscitation, selection, review, 335
tory depression, flumazenil therapy. 483 aminoglycosides; pharmacokinetics, prediction, 909 women; gender-related differences, FDA regulations,
Bezoars; nifedipine; toxicity, sustained-action tablets, creatinine; clearance, estimation, gynecologic neo- 395; new drugs, FDA regulations, 712
849 plasms, 685 zalcitabine, comparison, didanosine; AIDS therapy,
Binding phenytoin; dosage, unbound, blood levels prediction, efficacy, 391
phenytoin; proteins, unbound levels prediction, 913 913 Clomipramine; premenstrual syndrome; therapy, psy-
quinidine; plasma, effects, ultrafiltration, 917 vancomycin; dosage, computer programs, 126 chological symptoms, 181
Bioavailability, see Drugs, availability Cancer, see Antineoplastic agents Clonazepam; concomitant therapy, 222
Biotechnology; shock; septic, therapy, review, 829 Cancer drugs, see Antineoplastic agents Clonidine hydrochloride; lactation; maternal consump-
938 Clinical Pharmacy Vol 12 Dec 1993
Annual Index
tion, infant blood levels, 178 toxicity; pancreatitis, review, 440 induced, review, 117
Cobamamide; dietary supplements; athletes, ergogenic Dietary supplements; athletes; ergogenic effects, 900 metoclopramide; lactation stimulation, therapy, 479
effects, 900 Digoxin; atrial fibrillation; therapy, and atrial flutter, pamidronate disodium; hypercalcemia therapy, ma-
Cognition 721 lignancy-induced, review, 117
enalapril maleate, comparison, hydrochlorothiazide, Dimethyl sulfoxide; mechanism of action; anthracy- prednisone; allergic bronchopulmonary aspergillosis
propranolol hydrochloride; toxicity, hypertension cline extravasation therapy, 560 therapy, review, 24
therapy, 300 Diphtheria and tetanus toxoids and pertussis vaccines; Drug abuse; therapy; levomethadyl maintenance, nar-
hydrochlorothiazide, comparison, enalapril maleate, combination, Haemophilus b oligosaccharide conju- cotic treatment programs, 797
propranolol hydrochloride; toxicity, hypertension gate vaccines; marketing, FDA approvals, 391 Drug administration routes
therapy, 300 Diuretics leucovorin calcium, comparison, levoleucovorin cal-
propranolol hydrochloride, comparison, enalapril furosemide; toxicity, pancreatitis, review, 440 cium; i.v. vs. oral, equivalency, availability, 293
maleate, hydrochlorothiazide; toxicity, hyperten- hypertension; therapy, protocols, 53 levoleucovorin calcium, comparison, leucovorin cal-
sion therapy, 300 nephrotic syndrome; complications, therapy, review, cium; i.v. vs. oral, equivalency, availability, 293
Colitis 429 quinacrine hydrochloride; intrapleural, pleurodesis
cefixime; toxicity, metronidazole therapy, 881 premenstrual syndrome; fluid retention therapy, 181 solution, pneumothorax therapy, 693
mesalamine; ulcerative, therapy, FDA approvals, 555 thiazides; systolic hypertension therapy, geriatrics, Drug administration sites; intravenous; pressure, cath-
Colloids; replacement solutions; clinical studies, re- review, 347 eter extravasation prediction, infants, 216
view, 415; selection, clinical studies, review, 335 Documentation; drugs, adverse reactions; meDWatch, Drug administration; cladribine; leukemia therapy, re-
Combined therapy FDA programs, 529 view, 805
cyclosporine and methotrexate; graft vs. host disease, Dosage Drug information; new drugs; evaluative reviews, pub-
marrow transplantation, 736 aldesleukin; DUE criteria, 853 lications, need, 306
methotrexate and cyclosporine; graft vs. host disease, amlodipine besylate, 93 Drug interactions
marrow transplantation, 736 anti-inflammatory agents; nonsteroidal, DUE criteria, drugs, nonprescription; new labeling requirements,
ulcers; peptic, H. pylori, review, 34 780 FDA, 800
Commentaries, 53, 527 atovaquone, 175; P. carinii pneumonia, therapy, re- itraconazole, 6
Communication; clinical studies; results, prepublica- view, 563 sertraline hydrochloride and tranylcypromine sul-
tion clinical alerts, NIH, 637 cefepime; pharmacokinetics, cholecystectomy, acute fate; serotonergic syndrome, 222
Compounding; quinacrine hydrochloride; pleurodesis cholecystitis, 134 tranylcypromine sulfate and sertraline hydrochlo-
solutions, tablets, 693 ciprofloxacin; DUE criteria, 226 ride; serotonergic syndrome, 222
Computers; programs; calculations, vancomycin dos- cisapride, 876 Drug Reaction Alerts, 74, 161, 238, 318, 385, 465, 544,
age, 126 cladribine, 391; leukemia therapy, review, 805 624, 702, 785, 863, 932
Contraceptives, injectable; medroxyprogesterone ace- cyclosporine; DUE criteria, transplant recipients, 696 Drugs
tate; marketing, FDA approvals, 92 diphtheria and tetanus toxoids and pertussis vac- new; marketing, FDA approval, 1992, 247; publica-
Contraceptives, oral; premenstrual syndrome; therapy, cines, combination, Haemophilus b oligosaccharide tions, evaluative reviews, need, 306
181 conjugate vaccines; FDA approvals, marketing, 391 unapproved; imports, AIDS buyers’ clubs, FDA regu-
Contraindications; itraconazole, 6 enoxaparin, 471 lations, 632
Correction Notices, 14, 558, 803, 881 epoetin alfa; DUE criteria, 925 Drugs, adverse reactions
Are antiarrhythmic drugs obsolete? (Aug 1992 Com- felbamate, 713 see also Toxicity
mentary), 14 felodipine; hypertension therapy, review, 261 ondansetron hydrochloride; seizures, nausea therapy,
Cladribine approved as first-line therapy for hairy cell fentanyl; transdermal pain therapy, 718 613
leukemia (Jun 1993, News), 558 finasteride; prostatic hypertrophy therapy, review, 15 photosensitivity; allergies, review, 580
Flumazenil: a benzodiazepine antagonist (Sep 1993, flosequinan; high, toxicity, clinical studies, 474; high, replacement solutions; review, 335
Drug Review), 803 toxicity, product withdrawal, 713 reports; MEDWatch, FDA programs, 529
Zolpidem: a nonbenzodiazepine hypnotic for treat- flumazenil; DUE criteria, 536 temafloxacin hydrochloride; hemolytic anemia, kid-
ment of insomnia (Nov 1993, Drug Reviews), 881 gentamicin sulfate; term newborn twins, 615 ney failure, 380
Costs heparin; estimation, pharmacokinetic models, 597 Drugs, availability
anticoagulants; thrombophlebitis therapy, 892 indomethacin; injections, DUE criteria, neonates, 232 leucovorin calcium, comparison, levoleucovorin cal-
cladribine; leukemia therapy, review, 805 isradipine; hypertension therapy, review, 261 cium; equivalency, oral vs. i.v., 293
new-drug applications; Prescription Drug User Fee itraconazole, 6 levoleucovorin calcium, comparison, leucovorin cal-
Act of 1992, pharmaceutical industry, 3 lidocaine hydrochloride; protocols, pharmacokinetics cium; equivalency, oral vs. i.v., 293
replacement solutions; resuscitation, review, 335 monitoring, pharmacists’ role, 527 Drugs, body distribution
CP Continuing Education, 67, 154, 235, 314, 383, 460, lithium; DUE criteria, 617 aminoglycosides; pharmacokinetics, septic shock, 131
542, 622, 699, 783, 860, 929 lomefloxacin; DUE criteria, 452 clonidine hydrochloride; lactation, infant, blood lev-
Creatinine; clearance; estimation, gynecologic neo- loratadine, 474 els, 178
plasms, 685 medroxyprogesterone acetate, 92 gentamicin sulfate; term newborn twins, 615
Crystalloids; replacement solutions; clinical studies, re- meperidine hydrochloride; patient-controlled analge- midazolam hydrochloride; follicular fluid levels, in
view, 415; selection, clinical studies, review, 335 sia, DUE criteria, 150 vitro fertilization, 770
Current Literature, 74, 161, 238, 318, 385, 465, 544, 624, mesalamine, 555 vancomycin; pharmacokinetics, geriatrics, 481; pre-
702, 785, 863, 932 molgramostim; side effects, bone marrow transplan- diction, pharmacokinetics, 909
Cyclosporine tation, 520 vancomycin hydrochloride; pharmacokinetics, hema-
alone and with methotrexate; graft vs. host disease, morphine sulfate; patient-controlled analgesia, DUE tologic malignancy, 515
prophylaxis, marrow transplantation, 736 criteria, 150 Drugs, investigational
nephrotic syndrome; therapy, review, 429 ofloxacin; DUE criteria, 452 investigational new drugs; stavudine, AIDS therapy,
use; evaluation, criteria, transplant recipients, 696 overdose; benzodiazepines, flumazenil therapy, over- parallel track policy, 7
Cystic fibrosis view, 691; benzodiazepines, flumazenil therapy, re- new-drug applications; accelerated, FDA approvals,
quinacrine hydrochloride; pneumothorax therapy, view, 641; benzodiazepines, flumazenil-use criteria, final regulations, 253; clinical studies, women, FDA
pleurodesis solution, 693 536 regulations, 712; Prescription Drug User Fee Act of
therapy; review, 657 paclitaxel; refractory ovarian neoplasms therapy, re- 1992, FDA approvals, 3
Cytotoxic agents, see Antineoplastic agents view, 401 Drugs, nonprescription; labeling; FDA regulations, 800
phenytoin; unbound, blood levels prediction, equa- Drug use; evaluation; aldesleukin, criteria, 853; cipro-
tions, 913 floxacin, criteria, 226; cyclosporine, criteria, trans-
D sotalol hydrochloride, 176; arrhythmia therapy, re- plant recipients, 696; epoetin alfa, criteria, 925; fluma-
view, 883 zenil criteria, 536; indomethacin injections, criteria,
strontium chloride Sr 89, 632 neonates, 232; lithium, criteria, 617; lomefloxacin,
Dalteparin; thrombophlebitis; low molecular weight tacrine hydrochloride, 873 ofloxacin, criteria, 452; NSAIDs criteria, 780; patient-
heparins vs. unfractionated, 892 teniposide, 6 controlled analgesia, criteria, 150; ticlopidine, criteria,
Danazol; premenstrual syndrome; therapy, 181 ticlopidine; DUE criteria, 64 64; warfarin criteria, 307
Dependence; opiates; levomethadyl therapy, regula- vancomycin hydrochloride; calculations, computers, Ductus arteriosus; indomethacin; patent, therapy, DUE
tions, 797 126; pharmacokinetics, hematologic malignancy, criteria, neonates, 232
Depression; lithium; therapy, DUE criteria, 617 515 DUE Criteria, 64, 150, 226, 307, 452, 536, 617, 696, 780,
Devices; medical; clinical studies, women, FDA regula- warfarin; DUE criteria, 307 853, 925
tions, 712; reports, MeDWatch, FDA programs, 529 zolpidem tartrate; insomnia therapy, review, 814 aldesleukin, 853
Dextrans; replacement solutions; selection, clinical Dosage forms ciprofloxacin, 226
studies, review, 335 glycerin; enemas vs. suppositories, neonates, 846 cyclosporine, 696
Dialysis leucovorin calcium, comparison, levoleucovorin cal- epoetin alfa, 925
hemo-; therapy, temafloxacin adverse reactions, 380 cium; i.v. vs. oral, equivalency, availability, 293 flumazenil, 536
peritoneal; peritonitis, effects, a,-acid glycoprotein levoleucovorin calcium, comparison, leucovorin cal- indomethacin, 232
concentrations, 602 cium; i.v. vs. oral, equivalency, availability, 293 lithium, 617
Diarrhea; cefixime; toxicity, metronidazole therapy, 881 mesalamine; sustained-action, oral, FDA approvals, ofloxacin and lomefloxacin, 452
Diazepam; seizures; therapy, ondansetron adverse re- 555 nonsteroidal anti-inflammatory drugs (NSAIDs), 780
actions, 613 Dosage schedules patient-controlled analgesia, 150
Didanosine anti-inflammatory agents; nonsteroidal, long-term ticlopidine, 64
comparison, zalcitabine; AIDS therapy, efficacy, therapy, DUE criteria, 780 warfarin, 307
NIAID clinical studies, 391 gallium nitrate; hypercalcemia therapy, malignancy-
Vol 12 Dec 1993 Clinical Pharmacy 939
Annual Index
E enoxaparin marketing, 471; felbamate marketing, vancomycin hydrochloride; pharmacokinetics, hema-
713; itraconazole marketing, 6; loratadine market- tologic malignancy, 515
ing, 474; medroxyprogesterone marketing, 92; me- Haloperidol lactate; therapy; aggressive sex behavior,
Editorials, 306, 526, 691, 923 salamine marketing, 555; new drugs, evaluative re- propofol toxicity, 449
Context of a transition, 923 views, need, 306; new drugs, 1992, 247; sotalol mar- HA-1A see Nebacumab
Judicious use of flumazenil, 691 keting, 176; strontium chloride Sr 89 marketing, Hay fever; loratadine; therapy, FDA approvals, 474
The new AJHP, 526 632; tacrine marketing, 873; teniposide marketing, Health care; pharmacists; role, grants, appropriate drug
Reviews of new drugs, 306 6; Tetramune marketing, 391 use, 474
Education, pharmaceutical; residencies; pharmaceuti- labeling; new regulations, nonprescription drugs, 800; Heaith professions
cal care, ASHP, 923 proposed ruling, prescription, pediatrics, 6 role; MEDWatch, FDA programs, 529
Enalapril maleate; comparison, hydrochlorothiazide, MED Watch; medical product reporting program, 529 tuberculosis; surveillance programs, 167
propranolol hydrochloride; effects, cognition, motor Prescription Drug User Fee Act of 1992; laws, pharma- Heart failure; flosequinan; congestive, high dose, toxici-
activity, quality of life, 300 ceutical industry, 3 ty, 474
Encephalopathy; muromonab-CD3; toxicity, graft rejec- regulations; clinical studies, women, 395; levometha- Helicobacter infections; therapy; peptic ulcers, 34
tion therapy, 610 dyl maintenance, narcotic treatment programs, 797; Helicobacter pylori; therapy; peptic ulcers, review, 34
Endotoxins; shock; septic, therapy, review, 829 women, clinical studies, new drugs, 712 Hematologic diseases; vancomycin hydrochloride; neo-
Enemas; glycerin; vs. suppositories, neonates, 846 stavudine; AIDS therapy, parallel track policy ap- plasms, pharmacokinetics, dosage, 515
Enoxaparin provals, 7 Heparin
marketing; FDA approvals, 471 unapproved drugs; regulations, imports, AIDS buy- dosage; estimation, pharmacokinetic models, 597
thrombophlebitis; low-molecular-weight heparins vs. ers’ clubs, 632 low molecular weight; cerebrovascular disorders
unfractionated, 892 Forms; reports; MeDWatch, FDA programs, 529 therapy, review, 359
Enzymes; cystic fibrosis; digestive, therapy, 657 Formulations; quinacrine hydrochloride; pleurodesis myocardial infarction; therapy, 197
Epilepsy; felbamate; therapy, FDA approvals, 713 solutions, pneumothorax therapy, 693 Heparinoids; cerebrovascular disorders; therapy, re-
Epoetin alfa; use; evaluation, criteria, 925 Furosemide; toxicity; pancreatitis, review, 440 view, 359
Equations Heparins; thrombophlebitis; low-molecular-weight vs.
aminoglycosides; pharmacokinetics, prediction, 909 G unfractionated, 892
creatinine; clearance, estimation, gynecologic neo- Histoplasmosis; itraconazole; therapy, FDA approvals,
plasms, 685 6
heparin; dosage estimation, 597 HIV infections; protocols; altered immunocompetence,
phenytoin; unbound, blood levels prediction, meth- Gallium nitrate; hypercalcemia; therapy, malignancy- therapy, ACIP, 675
odology, 913 induced, review, 117 Hydrochlorothiazide; comparison, enalapril maleate,
Equivalency, generic Gastroesophageal reflux; cisapride; therapy, FDA ap- propranolol hydrochloride; effects, cognition, motor
leucovorin calcium, comparison, levoleucovorin cal- provals, 876 activity, quality of life, 300
cium; i.v. vs. oral, availability, 293 Gastrointestinal drugs Hyperalimentation, see Nutrition; parenteral
levoleucovorin calcium, comparison, leucovorin cal- bismuth; peptic ulcers, H. pylori, combined therapy, Hypercalcemia
cium; i.v. vs. oral, availability, 293 review, 34 gallium nitrate; therapy, malignancy-induced, re-
Equivalency, therapeutic cisapride; marketing, FDA approvals, 876 view, 117
fentanyl, comparison, morphine; dosage, pain, 718 mesalamine; FDA approvals, 555 pamidronate disodium; therapy, malignancy-in-
morphine, comparison, fentany!; dosage, pain, 718 metoclopramide; lactation stimulation, therapy, 479 duced, review, 117
Estrogen; premenstrual syndrome; therapy, 181 Gene therapy Hypernatremia; nutrition; parenteral, total, toxicity, 138
Estrogens cystic fibrosis; review, 657 Hypertension
estrogen; premenstrual syndrome therapy, 181 research; genetic disorders, neoplasms, review, 488 amlodipine besylate; therapy, FDA approvals, 93
toxicity; pancreatitis, review, 440 Genetic engineering; gene therapy; research, review, enalapril maleate, comparison, hydrochlorothiazide,
Excretion 488 propranolol hydrochloride; toxicity, quality of life,
N-acetyl-i-tyrosine; excretion, infants, parenteral nu- Gentamicin; pharmacokinetics; prediction, vancomycin 300
trition, 606 pharmacokinetics, 909 felodipine; therapy, review, 261
cefepime; clearance, cholecystectomy, acute cholecys- Gentamicin sulfate hydrochlorothiazide, comparison, enalapril maleate,
titis, 134 body distribution; pharmacokinetics, septic shock, propranolol hydrochloride; toxicity, quality of life,
creatinine; clearance, estimation, gynecologic neo- 131 300
plasms, 685 pharmacokinetics; term newborn twins, 615 isradipine; therapy, review, 261
gentamicin sulfate; term newborn twins, 615 Geriatrics propranolol hydrochloride, comparison, enalapril
mexiletine; clearance, middle-aged and elderly pa- hypertension; systolic, therapy, review, 347; therapy, maleate, hydrochlorothiazide; toxicity, quality of
tients, 768 protocols, 53 life, 300
vancomycin; clearance, prediction, 909; models, clear- mexiletine; pharmacokinetics, age, effects, 768 protocols; therapy, 53
ance, dosage calculations, 126 ticlopidine hydrochloride; toxicity, cholestasis, 398 therapy; systolic, geriatrics, review, 347
vancomycin hydrochloride; clearance, hematologic vancomycin; pharmacokinetics, 481 Hyperthyroidism; amiodarone; toxicity, 774
malignancy, 515 Ginseng; dietary supplements; athletes, ergogenic ef- Hypoalbuminemia; albumin human; therapy, effects,
Extravasation fects, 900 serum protein levels, 377
anthracyclines; toxicity, dimethyl sulfoxide therapy, Glycerin; dosage forms; enemas vs. suppositories, neo- Hyponatremia; nutrition; parenteral, total, toxicity, 138
560 nates, 846 Hypotensive agents
injections; i.v. pressure, prediction, infants, 216 Globulin immune clonidine hydrochloride; maternal consumption, lac-
graft vs. host disease; prophylaxis, bone marrow tation, infant blood levels, 178
transplantation, 736 enalapril maleate, comparison, hydrochlorothiazide,
& therapy; altered immunocompetence, ACIP, 675 propranolol hydrochloride; effects, cognition and
Glomerulonephritis; therapy; membranoproliferative, motor activity, quality of life, 300
review, 429 felodipine; therapy, review, 261
Fat emulsions; intravenous; respiratory tract diseases, Glomerulosclerosis; therapy; focal, review, 429 hydrochlorothiazide, comparison, enalapril maleate,
review, 276 Gonadorelin agonists; premenstrual syndrome; thera- propranolol hydrochloride; effects, cognition and
FDA Medical Products Reporting Form and Instruc- py, 181 motor activity, quality of life, 300
tions, 71, 531 Graft rejection hypertension; isolated systolic, geriatrics, review, 347
Felbamate; marketing; FDA approvals, 713 cyclosporine; prophylaxis, DUE criteria, transplant isradipine; therapy, review, 261
Felodipine; hypertension; therapy, review, 261 recipients, 696 propranolol hydrochloride, comparison, enalapril
Fentanyl citrate; concomitant therapy, 770 muromonab-CD3; therapy, encephalopathy toxicity, maleate, hydrochlorothiazide; effects, cognition
Fentanyl; dosage; transdermal pain therapy, 718 610 and motor activity, quality of life, 300
Fertilization in vitro; midazolam hydrochloride; follic- Graft vs. host disease; therapy; prophylaxis, bone mar- protocols; therapy, 53
ular fluid levels, 770 row transplantation, 736 Hypothyroidism; amiodarone; toxicity, 774
Filtration; ultra; effects, quinidine blood levels, 917 Grants; Agency for Health Care Policy and Research;
Finasteride; prostatic hypertrophy; therapy, review, 15 pharmacists’ role, health care, 474
Flosequinan Guidelines; National Institutes of Health; clinical stud-
product withdrawal; toxicity, 713 ies, news media, alerts, 637
toxicity; high dosage, clinical studies, 474 Guidelines, treatment, see Protocols
Flumazenil Iatrogenic diseases, see Drugs, adverse reactions
ratviioenwa,l 69t1h erapy; benzodiazepine overdose, over- H Immdiupnhitzhaetriiao na nd tetanus toxoids and pertussis and Hae-
therapy; benzodiazepine overdose, review, 641; respi- mophilus influenzae; conjugate vaccines, pediatrics,
ratory depression, benzodiazepine toxicity, 483 FDA approvals, 391
use; evaluation, criteria, 536 Haemophilus b oligosaccharide conjugate vaccines; Haemophilus influenzae; conjugate vaccines, low immu-
Fluoxetine; premenstrual syndrome; therapy, psycho- combination, diphtheria and tetanus toxoids and per- nogenicity, list, 176
logical symptoms, 181 tussis vaccines; marketing, FDA approvals, 391 tuberculosis; BCG vaccines, health professions, sur-
Food and Drug Administration (U.S.) Haemophilus b polysaccharide conjugate vaccines; im- veillance programs, 167
approvals; accelerated, final regulations, 253; amlo- munogenicity; low, list, 176 vaccines; altered immunocompetence, ACIP proto-
dipine marketing, 93; atovaquone marketing, 175; Half-life cols, 675
cisapride marketing, 876; cladribine marketing, 391; gentamicin sulfate; term newborn twins, 615 Immunoassay
vancomycin; pharmacokinetics, geriatrics, 481 enzyme multiplied; vs. fluorescence polarization, an-
940 Clinical Pharmacy Vol 12 Dec 1993
Annual Index
tiarrhythmic agents, 49 L Medroxyprogesterone acetate; marketing; FDA ap-
fluorescence polarization; vs. enzyme multiplied, an- provals, 92
tiarrhythmic agents, 49 Meperidine hydrochloride; use; evaluation, criteria, pa-
Immunocompetence; protocols; altered, globulin im- Labeling tient-controlled analgesia, 150
mune, immunization, ACIP, 675 drugs, nonprescription; FDA regulations, 800 Mercaptopurine; toxicity; pancreatitis, review, 440
Immunogenicity; Haemophilus b polysaccharide conju- pediatrics; prescriptions, FDA proposed ruling, 6 Mesalamine; marketing; FDA approvals, 555
gate vaccines; low, list, 176 Lactation Methodology
Immunologic deficiency syndromes; protocols; vac- clonidine hydrochloride; maternal consumption, in- clinical studies; women, FDA regulations, 712
cines, globulin immue, ACIP, 675 fant blood levels, 178 creatinine; clearance, estimation, gynecologic neo-
Immunosuppression; vitamin A; immunomodulating therapy; stimulation, 479 plasms, 685
effects, review, 506 Laws; Prescription Drug User Fee Act of 1992; pharma- heparin; dosage estimation, pharmacokinetic models,
Immunosuppressive agents ceutical industry, FDA approvals, 3 597
azathioprine; toxicity, pancreatitis, review, 440 Letters, 13, 178, 255, 398, 481, 718, 802, 881 injections; i.v. pressure, extravasation prediction, in-
cyclosporine; alone and with methotrexate, graft vs Clonidine and breast-feeding, 178 fants, 216
host disease, marrow transplantation, 736; DUE cri- Comment on ASHP therapeutic guidelines, 399 phenytoin; unbound, blood levels prediction, equa-
teria, transplant recipients, 696; nephrotic syn- Dosage of transdermal fentanyl, 718 tions, 913
drome, review, 429 Ketoconazole and gastric acidity, 802 quinidine; blood levels, effects, ultrafiltration, tem-
methotrexate; graft vs. host disease, marrow trans- Long-term dobutamine therapy, 13 perature, 917
plantation, 736 Pharmacokinetics of oxaprozin, 255 vancomycin; pharmacokinetics, prediction, 909
muromonab-CD3; toxicity, encephalopathy, graft re- Prophylaxis with aztreonam plus metronidazole dur- vancomycin hydrochloride; dosage, calculations,
jection therapy, 610 ing appendectomy, 803 computers, 126
tacrolimus; graft vs. host disease, marrow transplan- Recognition of severe cefixime-induced diarrhea, 881 Methotrexate
tation, 736 Relative safety and efficacy of pravastatin, 256 alone and with cyclosporine; graft vs. host disease,
thalidomide; graft vs. host disease, marrow trans- Sargramostim for sulfasalazine-induced agranulocy- prophylaxis, marrow transplantation, 736
plantation, 736 tosis, 179 asthma; therapy, overview, 762
Immunotherapy Ticlopidine-induced cholestatic jaundice, 398 N-5-Methyltetrahydrofolate; blood levels; leucovorin-
antithymocyte globulin; graft vs. host disease, mar- Use and safety of sumatriptan, 258 levoleucovorin generic equivalency, 293
row transplantation, 736 Vancomycin pharmacokinetics in elderly patients, Metoclopramide; lactation; stimulation, 479
globulin immune; graft vs. host disease, marrow 481 Metronidazole
transplantation, 736 Leucovorin calcium; comparison, levoleucovorin calci- and aztreonam; colorectal surgery, prophylaxis,
molgramostim; side effects, bone marrow transplan- um; equivalency, oral vs. i.v., availability, 293 ASHP protocols, 399
tation, 520 Leukemia diarrhea; therapy, cefixime toxicity, 881
nebacumab; clinical studies, marketing, withdrawal, cladribine; hairy cell, therapy, FDA approvals, 391; ulcers; peptic, combined therapy, H. pylori, review, 34
toxicity, 254 therapy, review, 805 Mexiletine; pharmacokinetics; effects, age, geriatrics,
protocols; altered immunocompetence, ACIP, 675 teniposide; lymphocytic, therapy, FDA approvals, 6 768
sargramostim; agranulocytosis therapy, sulfasalazine Levoleucovorin calcium; comparison, leucovorin calci- Midazolam hydrochloride; body distribution; follicular
toxicity, 179; dosage, 520 um; equivalency, oral vs. i.v., availability, 293 fluid levels, in vitro fertilization, 770
vitamin A; immunomodulating effects, review, 506 Levomethadyl acetate; therapy; maintenance, narcotic Minerals; and vitamins; dietary supplements, athletes,
zolimomab aritox; graft vs. host disease, marrow treatment programs, 797 ergogenic effects, 900
transplantation, 736 Levothyroxine sodium; hypothyroidism; therapy, ami- Models
Imports; unapproved drugs; AIDS buyers’ clubs, FDA odarone toxicity, 774 heparin; pharmacokinetics, dosage estimation, 597
regulations, 632 Lidocaine hydrochloride; pharmacokinetics; monitor- vancomycin; clearance, dosage calculations, 126
Indomethacin; use; evaluation, criteria, neonates, 232 ing, pharmacists’ role, 527 Molgramostim; toxicity; side effects, bone marrow
Industry, pharmaceutical Literature; new drugs; evaluative reviews, need, 306 transplantation, 520
advertising; accelerated drug approvals, FDA regula- Lithium; use; evaluation, criteria, 617 Morphine sulfate; use; evaluation, criteria, patient-con-
tions, 253 Lomefloxacin; use; evaluation, criteria, 452 trolled analgesia, 150
labeling; nonprescription drugs, FDA regulations, Loratadine; marketing; FDA approvals, 474 Morphine; equivalency, therapeutic; fentanyl, transder-
800; prescription drugs, pediatrics, FDA ruling, 6 mal dosage, 718
new-drug applications; clinical studies, women, FDA Mortality
regulations, 712 anticoagulants; myocardial infarction therapy, 197
Prescription Drug User Fee Act of 1992; laws, FDA flosequinan; high dose, toxicity, clinical studies, 474;
approvals, 3 toxicity, product withdrawal, 713
Infections; vitamin A; immunomodulating effects, re- Magnesium; myocardial infarction; therapy, mecha- Motor activity
view, 506 nism of action, review, 588 enalapril maleate, comparison, hydrochlorothiazide,
Injections Marketing propranolol hydrochloride; toxicity, hypertension
anthracyclines; extravasation, dimethyl sulfoxide amlodipine besylate; FDA approvals, 93 therapy, 300
therapy, 560 atovaquone; FDA approvals, 175 hydrochlorothiazide, comparison, enalapril maleate,
catheters; i.v. pressure, extravasation prediction, in- cisapride; FDA approvals, 876 propranolol hydrochloride; toxicity, hypertension
fants, 216 cladribine; FDA approvals, 391 therapy, 300
ciprofloxacin; intravenous therapy, infections, DUE diphtheria and tetanus toxoids and pertussis vac- propranolol hydrochloride, comparison, enalapril
criteria, 226 cines, combination, Haemophilus b oligosaccharide maleate, hydrochlorothiazide; toxicity, hyperten-
indomethacin; DUE criteria, neonates, 232 conjugate vaccines; FDA approvals, 391 sion therapy, 300
medroxyprogesterone acetate; marketing, FDA ap- enoxaparin; FDA approvals, 471 Mucolytic agents; cystic fibrosis; therapy, review, 657
provals, 92 felbamate; FDA approvals, 713 Muromonab-CD3; toxicity; encephalopathy, graft rejec-
Insomnia; zolpidem tartrate; therapy, review, 814 flosequinan; product withdrawal, 713 tion therapy, 610
Interleukin inhibitors; shock; septic, therapy, review, itraconazole; FDA approvals, 6 Mycobacterium tuberculosis; resistance; antitubercu-
829 loratadine; FDA approvals, 474 lars, health professions, surveillance programs, 167
Iodine I 131; hyperthyroidism; therapy, amiodarone medroxyprogesterone acetate; FDA approvals, 92 Myocardial infarction
toxicity, 774 mesalamine; FDA approvals, 555 magnesium; therapy, mechanism of action, review,
Isosorbide dinitrate; hypertension; systolic, therap’, nebacumab; clinical studies, withdrawal, toxicity, 254 588
geriatrics, review, 347 new drugs; evaluative reviews, need, 306; FDA ap- therapy, 197
Isradipine; hypertension; therapy, review, 261 proval, 1992, 247
Itraconazole; marketing; FDA approvals, 6 sotalol hydrochloride; FDA approvals, 176
strontium chloride Sr 89; FDA approvals, 632
tacrine hydrochloride; FDA approvals, 873
J teniposide; FDA approvals, 6
Measles; vitamin A; immunomodulating effects, re- Nadroparin; thrombophlebitis; low-molecular-weight
view, 506 heparins vs. unfractionated, 892
Joint National Committee on the Detection, Evalua- meD Watch; reports; FDA programs, 529 National Institute of Allergy and Infectious Diseases
tion and Treatment of High Blood Pressure; reports; Mechanism of action didanosine, comparison, zalcitabine; AIDS therapy,
hypertension therapy, protocols, 53 amiodarone; toxicity, thyroid dysfunction, 774 efficacy, clinical studies, 391
Journals atovaquone; P. carinii pneumonia, therapy, review, zalcitabine, comparison, didanosine; AIDS therapy,
American Journal of Hospital Pharmacy; merging, Clini- 563 efficacy, clinical studies, 391
cal Pharmacy, 526, 923 cladribine; leukemia therapy, review, 805 National Institutes of Health; guidelines; clinical stud-
Clinical Pharmacy; merging, AJHP, 526, 923 dimethyl sulfoxide; anthracycline extravasation ther- ies, news media, alerts, 637
apy, 560 National Institute on Drug Abuse; regulations;
K fmlaugmnaezseniiulm;; remvyioecwa, rd6i41a l infarction therapy, review, lgreavmosm,e t7h9a7d yl maintenance, narcotic treatment pro-
588 Nausea; ondansetron hydrochloride; therapy, adverse
replacement solutions; resuscitation, review, 335 reactions, seizures, 613
Kidney failure; temafloxacin hydrochloride; adverse re- temafloxacin hydrochloride; adverse reactions, hemo- Nebacumab; clinical studies; and marketing withdraw-
actions, hemolytic anemia, 380 lytic anemia, 380 al, toxicity, 254
vitamin A; immunomodulating effects, review, 506 Neoplasms
aldesleukin; therapy, DUE criteria, 853
Vol 12 Dec 1993 Clinical Pharmacy 941
Annual Index
creatinine; clearance, estimation, gynecologic neo- prophylaxis against Mycobacterium avium complex, Patients
plasms, 685 797 drugs, personal; unapproved, imports, AIDS buyers’
epoetin alfa; anemia therapy, DUE criteria, 925 Radiopharmaceutical approved for relief of pain clubs, FDA regulations, 632
gallium nitrate; hypercalcemia therapy, malignancy- caused by bone metastases, 632 inpatients; lithium, DUE criteria, 617; lomefloxacin,
induced, review, 117 Sixteen PedvaxHIB vaccine lots have low immunoge- ofloxacin, DUE criteria, 452; NSAIDs, DUE criteria,
gene therapy; research, review, 488 nicity, 176 780; ticlopidine, DUE criteria, 64; warfarin, DUE
pamidronate disodium; hypercalcemia therapy, ma- Sotalol marketed for life-threatening arrhythmias, 176 criteria, 307
lignancy-induced, review, 117 Stavudine made available under parallel track policy, outpatients; flumazenil, DUE criteria, 536; lithium,
vancomycin hydrochloride; hematologic, pharmaco- DUE criteria, 617; lomefloxacin, ofloxacin, DUE cri-
kinetics, dosage, 515 Study provides additional support for warfarin use teria, 452; NSAIDs, DUE criteria, 780; ticlopidine,
Nephrosis; therapy; lipoid, therapy, review, 429 by patients with atrial fibrillation, 93 DUE criteria, 64; warfarin, DUE criteria, 307
Nephrotic syndrome; therapy; review, 429 Study shows deleterious effects from digoxin with- Pediatrics
News, 3, 91, 167, 247, 327, 391, 471, 551, 632, 712, 793, 873 drawal, 713 N-acetyl-.-tyrosine; excretion, infants, parenteral nu-
Acyclovir should not be used routinely for chicken- Study shows diazepam use during febrile illnesses trition, 606
pox, says pediatrics academy, 175 reduces risk of recurrent febrile seizures, 800 acyclovir; chickenpox therapy, AAP recommenda-
AHA issues report on Kawasaki disease, 555 Surveillance study adds to database on seroconver- tions, 175
AHCPR awards 14 grants for patient outcomes re- sion rates and zidovudine use after occupational bronchiolitis; therapy, review, 95
search, 474 exposures, 636 chloral hydrate; AAP recommendations, 876
American Heart Association updates life support Tacrine granted marketing approval for Alzheimer’s clonidine hydrochloride; maternal consumption, lac-
guidelines, 171 disease, 873 tation, infant blood levels, 178
Amlodipine approved for hypertension, angina ther- Teniposide granted marketing approval, 6 diphtheria and tetanus toxoids and pertussis vac-
apy, 93 Three categories of nonprescription drug products to cines, combination, Haemophilus b oligosaccharide
Atovaquone to be marketed as oral therapy for Pneu carry new warnings, 800 conjugate vaccines; immunization, FDA approvals,
mocystis carinii pneumonia, 175 Upcoming Specialty Meetings, 7, 93, 254, 331, 395, 475, 391
Book correction notice, 637 558, 637, 800, 879 Haemophilus b polysaccharide conjugate vaccines; low
CDC issues recommendations for rehydration and News media; clinical studies; clinical alerts, NIH guide- immunogenicity, list, 176
nutritional therapy for children with acute diar- lines, 637 injections; i.v. pressure, catheter extravasation predic-
rhea, 92 Nifedipine; toxicity; bezoars, sustained-action tablets, tion, infants, 216
CDC revises AIDS case definition, 254 849 neonates; gentamicin pharmacokinetics, term new-
Centocor suspends HA-1A testing, halts foreign sales, Nomograms born twins, 615; glycerin enemas vs. suppositories,
254 phenytoin; dosage, unbound, blood levels prediction, 846; indomethacin injections, DUE criteria, 232
Cisapride marketed for use in gastroesophageal re- 913 prescriptions; labeling, FDA proposed ruling, 6
flux disease, 876 vancomycin hydrochloride; initial dosage schedules, teniposide; lymphocytic leukemia therapy, FDA ap-
Cladibrine approved as first-line therapy for hairy cell hematologic malignancy, 515 provals, 6
leukemia, 391 Nutrition Penicillins; amoxicillin; peptic ulcers, H. pylori, com-
Combination vaccine approved for use in children, diet; and supplements, athletes, review, 900 bined therapy, review, 34
391 parenteral; N-acetyl-L-tyrosine, excretion, infants, 606; Pentamidine; toxicity; pancreatitis, review, 440
Conference, reports address public-health implica- albumin effects, serum protein levels, hypoalbu- Peritonitis; dialysis; peritoneal, effects, a,-acid glyco-
tions of tuberculosis, 167 minemia, 377; total, toxicity, sodium disorders, 138 protein concentrations, 602
Consensus recommendations for antithrombotic ther- support; respiratory tract diseases, review, 276 Pharmacists; role; health care, grants, 474; lidocaine,
apy updated, 92 pharmacokinetics monitoring, 527
Conptediinauterdi cs usaec aodf ecmhyl,o ra8l7 6 hydrate justified, concludes oO PhaPrhamramcaecuitsitcsa; l joucranrea;l s, Ammeerrgiicnagn, 9S2o3c iety of Hospital
Easier-to-use pirbuterol inhaler marketed, 715 Pharmaceutical services; research; grants, appropriate
FDA clears 26 new drugs for marketing in 1992, 247 drug use, 474
FDA issues regulations on accelerated drug-approval Octacosanol; dietary supplements; athletes, ergogenic Pharmacodynamics; atovaquone; P. carinii pneumonia,
process, 253 effects, 900 therapy, review, 563
FDA plans policy change on inclusion of women in Ofloxacin; use; evaluation, criteria, 452 Pharmacokinetics
clinical trials, 395 Ondansetron hydrochloride; adverse reactions; sei- N-acetyl-.-tyrosine; excretion, infants, parenteral nu-
FDA proposes more stringent pediatric-use labeling zures, nausea therapy, 613 trition, 606
of prescription drug products, 6 Opiates; levomethadyl acetate; maintenance therapy, aminoglycosides; body distribution, septic shock, 131;
FDA reiterates personal-use importation policy to narcotic treatment programs, 797 prediction, vancomycin pharmacokinetics, 909
buyers’ clubs, 632 Organizations; American Society of Hospital Pharma- amlodipine besylate, 93
FDA user fees approved, 3 cists; AJHP, Clinical Pharmacy, merging, 526, 923 atovaquone, 175; P. carinii pneumonia, therapy, re-
Flosequinan withdrawn from market, 713 Ovarian neoplasms; paclitaxel; refractory, therapy, re- view, 563
Four-drug regimen, directly observed therapy urged view, 401 cefepime; cholecystectomy, acute cholecystitis, 134
for initial tuberculosis therapy, 793 Oxygen radical scavengers; dimethyl] sulfoxide; anthra- cisapride, 876
Guidelines for release of clinical alerts set, 637 cycline extravasation therapy, 560 cladribine, 391; leukemia therapy, review, 805
Higher folic acid intake could prevent many common enoxaparin, 471
birth defects, says pediatrics academy, 879 P felbamate, 713
Intensive care units see increase in resistant entero- felodipine; hypertension therapy, review, 261
cocci, 797 finasteride; prostatic hypertrophy therapy, review, 15
Itraconazole released for blastomycosis and histoplas- flumazenil; review, 641
mosis therapy, 6 Paclitaxel; ovarian neoplasms; refractory, therapy, re- gentamicin sulfate; term newborn twins, 615
L.V. antimicrobials not indicated for presumed Lyme view, 401 heparin; models, dosage estimation, 597
disease, say rheumatology, infectious diseases Pain isradipine; hypertension therapy, review, 261
groups, 876 anti-inflammatory agents; nonsteroidal, long-term itraconazole, 6
Levomethady] acetate to be used in narcotic treatment therapy, DUE criteria, 780 lidocaine hydrochloride; monitoring, pharmacists’
programs, 797 fentanyl; transdermal therapy, dosage, 718 role, 527
Low-molecular-weight heparin to be marketed, 471 patient-controlled analgesia; therapy, DUE criteria, loratadine, 474
Medroxyprogesterone acetate granted contraceptive 150 medroxyprogesterone acetate, 92
indication in U.S., 92 strontium chloride Sr 89; therapy, bone neoplasms, mesalamine, 555
New antiepilepsy drug, felbamate, marketed, 713 FDA approvals, 632 mexiletine; effects, age, geriatrics, 768
New FDA policy encourages inclusion of women in Pamidronate disodium; hypercalcemia; therapy, malig- paclitaxel; refractory ovarian neoplasms therapy, re-
clinical trials, 712 nancy-induced, review, 117 view, 401
News Briefs, 7,93, 176, 254, 331, 395, 474, 555, 637, 715, Pancreatitis sotalol hydrochloride, 176; arrhythmia therapy, re-
879 asparaginase; toxicity, review, 440 view, 883
Nonionic contrast medium for MRI procedures mar- azathioprine; toxicity, review, 440 strontium chloride Sr 89, 632
keted, 93 didanosine; toxicity, review, 440 tacrine hydrochloride, 873
Nonsedating antihistamine approved by FDA, 474 estrogens; toxicity, review, 440 teniposide, 6
Nutrition support guidelines published, 715 furosemide; toxicity, review, 440 vancomycin; geriatrics, 481; prediction, aminoglyco-
Oral mesalamine formulation to be marketed, 555 mercaptopurine; toxicity, review, 440 side pharmacokinetics, 909
Patient deaths halt fialuridine trials, 715 pentamidine; toxicity, review, 440 vancomycin hydrochloride; dosage, hematologic ma-
Pediatrics academy releases guidelines for prevention sulfonamides; toxicity, review, 440
of neonatal group B streptococcal infection, 91 sulindac; toxicity, review, 440 zolpidem tartrate; insomnia therapy, review, 814
Physician group releases guidelines on preventive tetracyclines; toxicity, review, 440 Pharmacy and therapeutics committee; new drugs; de-
hormonal therapy, 327 thiazides; toxicity, review, 440 cisions, evaluative reviews, need, 306
Preliminary data show mortality risk from high-dose valproic acid; toxicity, review, 440 Pharmacy, institutional, hospital; quality assurance;
flosequinan, 474 Parenterals, see Injections programs, aldesleukin DUE criteria, 853; programs,
Preliminary study analysis suggests similar efficacy Patches transdermal; fentanyl; dosage, pain therapy, ciprofloxacin, DUE criteria, 226; programs, cyclospo-
for didanosine and zalcitabine, 391 718 rine DUE criteria, 696; programs, epoetin alfa DUE
Preliminary study findings fuel debate over timing of Patient-controlled analgesia; protocols; DUE criteria, criteria, 925; programs, flumazenil DUE criteria, 536;
zidovudine therapy, 551 150 programs, indomethacin injections, DUE criteria, neo-
Public Heaith Service issues recommendations for nates, 232; programs, lithium DUE criteria, 617; pro-
942 Clinical Pharmacy Vol 12 Dec 1993
Annual Index
grams, lomefloxacin, ofloxacin, DUE criteria, 452; pro- Publications Ss
grams, NSAIDs, DUE criieria, 780; programs, patient- American Society of Hospital Pharmacists; AJHP,
controlled analgesia, DUE criteria, 150; programs, Clinical Pharmacy, merging, 526, 923
ticlopidine DUE criteria, 64; programs, warfarin DUE new drugs; evaluative reviews, need, 306 Sargramostim
criteria, 307 Purchasing; unapproved drugs; AIDS buyers’ clubs, agranulocytosis; therapy, sulfasalazine toxicity, 179
Pharmacy, institutional; new drugs; evaluative re- FDA regulations, 632 comparison, molgramostim; dosage, 520
views, need, 306 Sclerosing agents; quinacrine hydrochloride; pneumo-
Phebnoyutnodi nc;o ncbelnotorda tiolnev,e ls9;1 3 prediction, equations, un- Q t69h3o rax therapy, pleurodesis solutions, cystic fibrosis,
Photosensitivity; drugs; toxicity, review, 580 Seizures; ondansetron hydrochloride; adverse reac-
Placental transfer; procainamide hydrochloride; lack, tions, nausea therapy, 613
neonates, 58 Quality assurance; hospital pharmacy; programs, al- Self-study Materials, 243, 548
Platelet aggregation inhibitors desleukin DUE criteria, 853; programs, ciprofloxacin, Concepts in Immunologaynd Immunotherapeutics, Second
glomerulonephritis; membranoproliferative, therapy, DUE criteria, 226; programs, cyclosporine DUE crite- Edition, 243
review, 429 ria, 696; programs, DUE criteria, 64; programs, epoe- Pharmacotherapy Self-Assessment Program: Module 1,
ticlopidine; DUE criteria, 64 tin alfa DUE criteria, 925; programs, flumazenil; DUE Cardiovascular, 244
Pneumonia; atovaquone; P. carinii, therapy, FDA ap- criteria, 536; programs, indomethacin injections, DUE Pharmacotherapy Self-Assessment Program: Module 2, In-
provals, 175; P. carinii, therapy, review, 563 criteria, neonates, 232; programs, lithium DUE crite- fectious Diseases, 548
Pneumothorax; quinacrine hydrochloride; therapy, ria, 617; programs, lomefloxacin, ofloxacin, DUE crite- Sertraline hydrochloride; interactions; tranylcypro-
pleurodesis solution, cystic fibrosis, 693 ria, 452; programs, NSAIDs, DUE criteria, 780; pro- mine, serotonergic syndrome, 222
Polymyalgia rheumatica; therapy; review, 571 grams, patient-controlled analgesia, DUE criteria, 150; Sex behavior; propofol; aggressive, toxicity, 449
Postmarketing surveillance programs, warfarin DUE criteria, 307 Sex
drugs, adverse reactions; MeDWatch, FDA programs, Quality of life clinical studies; women, FDA regulations, 395
529 enalapril maleate, comparison, hydrochlorothiazide, patients; effects, lack, heparin dosage estimation, 597
regulations; FDA accelerated drug approvals, 253 propranolol hydrochloride; cognition and motor Shock
Prednisolone; polymyalgia rheumatica; therapy, re- activity, effects, hypertension therapy, 300 aminoglycosides; septic, body distribution, 131
view, 571 hydrochlorothiazide, comparison, enalapril maleate, therapy; septic, biotechnology, review, 829
Prednisone propranolol hydrochloride; cognition and motor Smoking; effects; heparin dosage estimation, 597
aspergillosis; allergic bronchopulmonary, therapy, re- activity, effects, hypertension therapy, 300 Sodium chloride
view, 24 propranolol hydrochloride, comparison, enalapril injections; replacement solutions, selection, clinical
polymyalgia rheumatica; therapy, review, 571 maleate, hydrochlorothiazide; cognition and motor studies, review, 335
Pregnancy; procainamide hydrochloride; side effects, activity, effects, hypertension therapy, 300 replacement solutions; clinical studies, review, 415
lack, 58 Quinacrine hydrochloride; pneumothorax; therapy, Solutions; quinacrine hydrochloride; pleurodesis,
Premenstrual syndrome; therapy; review, 181 pleurodesis solution, cystic fibrosis, 693 pneumothorax therapy, 693
Prescription Drug User Fee Act of 1992; laws; pharma- Quinidine Sotalol hydrochloride
ceutical industry, FDA approvals, 3 binding; plasma, effects, ultrafiltration, 917 arrhythmia; therapy, review, 883
Prescriptions; drugs; appropriate use, grants, pharma- blood levels; fluorescence polarization vs. EMIT, 49 marketing; FDA approvals, 176
cists’ role, 474; pediatric labeling, FDA proposed rul- Quinolones Starches; replacement solutions; selection, clinical stud-
ing, 6 ciprofloxacin; DUE criteria, 226 ies, review, 335
Pressure; catheters; extravasation prediction, infants, lomefloxacin; DUE criteria, 452 Stavudine; acquired immunodeficiency syndrome;
216 ofloxacin; DUE criteria, 452 therapy, parallel track policy, FDA approvals, 7
Procainamide; blood levels; fluorescence polarization photosensitivity; toxicity, review, 580 Steroids, cortico-
methods, 49 temafloxacin hydrochloride; adverse reactions, hemo- asthma; dependent, methotrexate therapy, overview,
Procainamide hydrochloride; toxicity; side effects, lack, lytic anemia, 380 762
pregnancy, 58 cystic fibrosis; therapy, review, 657
Product withdrawal R graft vs. host disease; prophylaxis, bone marrow
flosequinan; toxicity, high dose, 713 transplantation, 736
nebacumab; foreign market, toxicity, 254 nephrotic syndrome; therapy, review, 429
ProDfreusgs ioUnsaelr Ffeeees ;A cnt ewof- d1r9u9g2, apphplaircmaatcieountsi; caPlr esicnrdiupsttiroyn, Radiopharmaceuticals; strontium chloride Sr 89; FDA prevdineiws, ol5o7n1e ; polymyalgia rheumatica therapy, re-
PPrroo3gg eessttienrso;n e;p ropgreesmteernosnter;u alp resmyenndsrtormuea;l tshyenrdapryo,m e 181t her- Rataaipcoypncraloolvv ailrts;h, e rc6ah3pi2yc kenpox, AAP recommendations, 175 pretpdyhn,ei rsraoepnvyi,ee ;w r,e avli5le7ew1r ,gi c2 4b; rpoonlcyhmoypaulglimao narrheyu maatspiecrag iltlhoesrias-
PPPPPPPrrrrrrroooooaoeaortaspspppactoshcttotytyroneytaeaif,lecacrt,atv ot onil aiiglhltopotc1tl;iisvyy8lh o sa,i o1,yox; rnhu idlt ;rcdyoqr i1apxicuot8iciaenhcy1cpiclr , yhirilh tdtlot;iyrro7fy ;icoor7l nk4pcooho eahhhxtfignalyhy bgcpoi;plirioira etfnexziroe;s,f idtr sideshin3e;;yttav0 ; hrsh0e eto e cerriproasaderiepmpfiedxypfys em,ea,;mc e br t;neisD hs,tsAU ahtoAvEerntiPrc uh,oao e arpgcrl,rnyaeir i ,nptt eaye4irlc,r4soia o9enayp v,,mnr ia midem2lerwi2 mn,oo6o dmm dtaaeao1l-;-5r- RegfnfcrFeululeoitnsulpoe3snrcrtemlaliidc9liaasacctaur5 t,nrszabii ic,yclesp ooehlh an,ntmn;;y6ni ;i ;esspld o 6nt ; nop3uuttp 2ahd,rna;Didlab ra aerrrbeenspwu7umnnus;pg1otgaz md8sremc oie ,roewydrn avn,Aoimle8e,d am,a0mdm 0zleig;i e nra mcnpa,l,oipdniip n rsrtnnaiesutiei3tsc,ggr n7aco seal7 rr,nt4o ii d7ivptsne4oethitg rrnieum,-d;odrp ron iaoesseprsls,eytel,a ,s,ar t , blue neaomdlbemv AiewoenlI rrpgidDvr,npidiSg ofhre, tfuiw eeng,nbirpos uneeen,y n dp ec6irler97aeers1s1tve-, ’2--- SSSSSSSttuuuuuolrlp6slrttarfoi3puohgfmaa2xnlnoeeoigtsi fdtsrrehnncaaaaiiy;ieoalscptut r gaam;yyomallzc;,i r pai yl diyztancpee,icod1eoas nxsh7r;nsie;9il c1ci; bori7d irte9tgeniya otles;dxtoy; ;iexic cit peicialrtisSnieytp,rcn;yuo r; ,kse 8retaa9eavmotg;svgiip .rirt aeameai rnewasnaun,r,uttle klhiomeoe4rvcatcr4eyesiya0vt ,ntp io gyoess,s;wien i ,spes t,ro,Fie n4 cDva4 i0tsAse eaa swsrrh,,aggo pcrr8pk8aa0,r4mm5 o6oo vssbattloiisdmm,y
aacAlhnmdltbte7oeiii8rrsao-0ailln il sce n,uap fknrlhio1 yan7pd;m5Shr moyaacltDitaUeeoxE;tri yysc , rp oiefatd cgeioHeralnotiotsrarspi,e;ci c stt,a8an 5llo3 n AsPsAthueParr rgoemirardycae,ilc s,ot 3ms9m;D9 e UnEadn atticrimiiotcnerrsio,a-, Relnapelelvbwm2ateou5e-cr3mmndea ietlrm ntue hngnpua trhtdor uyaigmlpstraipo aonllmni;uas,ct c ,aie teot3ifan77fot7se9ne c7s;t ;s , maasciecnretlueemrn aatpnercdoe,t, e iFnD naAlr ecvoeatlpisp,c r opvatarreleasnt,-- acenentfod4pciexi7hr-ps1oaoi tiltpnremoafciecerybo;cisult nttsi;ii,vpt o ehin sta3,,h9 ra 9rmg 1oae13mc3n14bto sok;si insec toilpocrrsoe,pc thaylcl,ha oxlipesrc,o ypshFtyDelAcat xoiamspy,p, r oAvaSaclHustP,e
cechifiiyplymmpcou8pmmArlem7ouoCuota6tnfIsinz eilPpneoonz,o ntxsar ihaaiiltlc6evn;ifi7re aeon5;; an; D p ;aDUy gDUDE;eUEUv n Eat Ecsc acr;clii rctctnirreetteiirrethstiere,eeaidrr ,rai i a,aaa ,p,5il y 39tm,62et2m r5r2eu a65dnn 3 s opiclmoamnmtup neotrececonimcpipeee,nt tse,nA cC6Ie9P,6, RReeprsdhgeoreyesruapnc54ugtlree28sisscr 98cn, th ii te tchanaaeltsd riivaosoepntnr;yu;s ;d e i cetlgshie,renn eireacarctaeptilvyi ci,o e nswsdtp,;uir dsoiot3eMro3sedc5,eDo rWlsasr,t,e cvhi5ne,3ew o,p FlDa4A1s5m ;s p,sr eolrgeercvtaiimeosnw,,, SSuysepmamnptlaipe oatfsacreifieiratlatedinl,hutiine taeopntdt9rmil -ei-2incrya5aae ,not lc ;nefitt ta;1chi;r 5te ooo0rnlaxo aa irlngpaceeeylimdnm t,e tyi dms,aaai; 7 nr c2bak1ae{lt;etzg h btoieeliaohsronriynacsgappsk,,;ye e ,rr s8tpF;4eonD 9nseA asoot iprpoielaanrpal a pstrmftioishvbv,erea ir llaslDpp,aayUt i,iEn o5 ,n5 ,p5 cr DroaiUtttroEei---
liindd6moo7oc5mna eiittnhoear ciinhngy;,d ropichnhjalerocmtraiicodiness;,t s’D dUoErso alegc,er ,i5 t2er7pi ah,a rnmeaocnoaktiesn,e ti2c3s2 RReesspfipehssiatsrriaamontnacosec,r;y y ; s autnrgrtvraieactintu tlbslde,ai rnsccaeuepal psareprsosr;p;o r girnMaau.tmt ers it,tu dibroe1nru6;cg7u loutsshiees,r, a 4p7hy4e, a ltrhe viperwo,- Sycvamoeiplresaow,s ,to h5l33so;4,m 7 is ytmsheteotrlaiipccy ,h yappgeeedrnittatesr;ni scis§o,n argetovhnieierswat,ps y;, 9 5;bg recoryinsactthiriicoc lsif,it birrsoe,--
olplstifaotitltmcaaholievpixoefupuapnldmcritoi;iod-xn nivcae;naoc;D eln i;UstnD ,Er;AU oD IElU7Dlc D ESreUi dctEr eic trtriaheiacnret,riare iarlat,i6gpe a1eyr,7s4i, a i5 ,a62 4; p 4ar5Da2l UlEel ctrirtaecrki a,p ol1i5c0y , FDA RRRieibsn2rlaug7eevsce6vtic riiri'eoitwsnna, ,;t iic4nolb1jni5re;n;oci nctcsaihreloi lenoep slcltitulatidaicoicnseet,;msa e,tc entldhtri;e ne rivacsirapoeelylw p,u,l st atipu3coedn3edis5mie; aes tn,r tci lrciesns,vio iclearulwet ,iv oisnet3swu3;d,5 i e9sse5,- TabTsils e ttsh erapy, review, 657
warfarin; DUE criteria, 307 nifedipine; sustained-action, bezoars, toxicity, 849
Vol 12 Dec 1993 Clinical Pharmacy 943
Annual Index
quinacrine hydrochloride; formulations, pleurodesis propranolol hydrochloride; effects, cognition and Transplantation
solutions, pneumothorax therapy, 693 motor activity, quality of life, 300 bone marrow; homologous, graft vs. host disease,
Tacrine hydrochloride; marketing; FDA approvals, 873 enoxaparin, 471 prophylaxis, 736; molgramostim toxicity, 520
Tacrolimus; graft vs. host disease; prophylaxis, bone epoetin alfa; DUE criteria, 925 organs; cyclosporine, DUE criteria, 696
marrow transplantation, 736 estrogens; pancreatitis, review, 440 Tranylcypromine sulfate; interactions; sertraline, sero-
Tamoxifen; premenstrual syndrome; therapy, masto- felbamate; side effects, 713 tonergic syndrome, 222
dynia, 181 felodipine; side effects, hypertension therapy, review, Trauma; replacement solutions; head, resuscitation,
Temafloxacin hydrochloride; adverse reactions; hemo- 261 clinical studies, review, 415
lytic anemia, kidney failure, 380 fentanyl; inappropriate dosage recommendations, Tuberculosis; Interscience Conference on Antimicrobial
Temperature; quinidine; effects, blood levels, ultrafii- menufacturer, 718 Agents and Chemotherapy; surveillance programs,
tration, 917 finasteride; side effects, prostatic hypertrophy thera- health professions, immunization, 167
Teratogenicity; procainamide hydrochloride; pregnan- py, review, 15 Tumor necrosis factor-a inhibitors; shock; septic, thera-
cy, 58 flosequinan; high dose, increased mortality, clinical py, review, 829
Tetracycline; bismuth and metronidazole; peptic ulcer studies, 474; side effects, product withdrawal, 713
therapy, H. pylori, review, 34 flumazenil; DUE criteria, 536; review, 641 U
Tetracyclines furosemide; pancreatitis, review, 440
photosensitivity; toxicity, review, 580 gallium nitrate; hypercalcemia therapy, malignancy-
tetracycline; peptic ulcers, H. pylori, combined thera- induced, review, 117
py, review, 34 glycerin; enemas vs. suppositories, neonates, 846 Ulcers
toxicity; pancreatitis, review, 440 heparins; low-molecular-weight vs. unfractionated, amoxicillin; peptic, H. pylori, combined therapy, re-
Tetrahydrofolic acid; blood levels; leucovorin—levoleu- side effects, 892 view, 34
covorin generic equivalency, 293 hydrochlorothiazide, comparison, enalapril maleate, bismuth; peptic, H. pylori, combined therapy, review,
Tetramune; diphtheria and tetanus toxoids and pertus- propranolol hydrochloride; effects, cognition and 34
sis vaccines; combination, Haemophilus b oligosaccha- motor activity, quality of life, 300 metronidazole; peptic, H. pylori, combined therapy,
ride conjugate vaccines, 391 indomethacin; injections, DUE criteria, neonates, 232 review, 34
Thalidomide; graft vs. host disease; prophylaxis, bone injections; extravasation, prediction, i.v. pressure, in- tetracycline; peptic, H. pylori, combined therapy, re-
marrow transplantation, 736 fants, 216 view, 34
Theophylline; cystic fibrosis; therapy, review, 657 isradipine; side effects, hypertension therapy, review, United States Public Health Service; Advisory Com-
Therapy Consultation, 479, 560 261 mittee on Immunization Practices; protocols, vac-
Dimethyl sulfoxide for treating anthracycline extrava- itraconazole; side effects, 6 cines, immune globulin, altered immunocompetence,
sation, 560 lidocaine hydrochloride; monitoring, pharmacists’ 675
Increasing breast milk supply, 479 role, 527 Urinary tract infections
Thiazides lithium; DUE criteria, 617 ciprofloxacin; therapy, DUE criteria, 226
hypertension; systolic, therapy, geriatrics, review, 347 lomefloxacin; DUE criteria, 452 lomefloxacin; therapy, DUE criteria, 452
photosensitivity; adverse reactions, review, 580 loratadine, 474 ofloxacin; therapy, DUE criteria, 452
toxicity; pancreatitis, review, 440 medroxyprogesterone acetate; side effects, 92
Thromboembolism; warfarin; prophylaxis, DUE crite- meperidine hydrochloride; patient-controlled anaige- V
ria, 307 sia, DUE criteria, 150
Thrombolytic agents; cerebrovascular disorders; thera- mercaptopurine; pancreatitis, review, 440
py, review, 359 mesalamine, 555
Thrombophlebitis; heparins; low-molecular-weight vs. methotrexate; side effects, asthma therapy, overview, Vaccines
unfractionated, 892 762 BCG; immunization, tuberculosis, surveillance pro-
Thrombosis; enoxaparin; prophylaxis, FDA approvals, molgramostim; side effects, bone marrow transplan- grams, 167
471 tation, 520 diphtheria and tetanus toxoids and pertussis vac-
Thyroid drugs; levothyroxine sodium; hypothyroidism morphine sulfate; patient-controlled analgesia, DUE cines, combination, Haemophilus b oligosaccharide
therapy, 774 criteria, 150 conjugate vaccines; FDA approvals, marketing, 391
Ticlopidine hydrochloride; toxicity; cholestasis, 398 muromonab-CD3; encephalcpathy, graft rejection Haemophilus b polysaccharide conjugate; low immu-
Ticlopidine; use; evaluation, criteria, 64 therapy, 610 nogenicity, list, 176
Tinzaparin; thrombophlebitis; low-molecular-weight nebacumab; clinical studies, marketing, withdrawal, immunization; altered immunocompetence, ACIP
heparins vs. unfractionated, 892 254 protocols, 675
Tobramycin sulfate; body distribution; pharmacokinet- nifedipine; bezoars, sustained-action tablets, 849 Valproic acid; toxicity; pancreatitis, review, 440
ics, septic shock, 131 nutrition; parenteral, total, sodium disorders, 138 Vancomycin; pharmacokinetics; geriatrics, 481; predic-
Tobramycin; pharmacokinetics; prediction, vancomy- ofloxacin; DUE criteria, 452 tion, aminoglycoside pharmacokinetics, 909
cin pharmacokinetics, 909 paclitaxel; side effects, refractory ovarian neoplasms Vancomycin hydrochloride
Toxicity therapy, review, 401 dosage; calculations, computers, 126
see also Drugs, adverse reactions pamidronate disodium; hypercalcemia therapy, ma- pharmacokinetics; dosage, hematologic malignancy,
aldesleukin; DUE criteria, 853 lignancy-induced, review, 117 515
amiodarone; thyroid dysfunction, therapy, 774 pentamidine; pancreatitis, review, 440 Vitamin A; mechanism of action; immunomodulating
amlodipine besylate; side effects, 93 procainamide hydrochloride; side effects, lack, preg- effects, review, 506
anthracyclines; extravasation, dimethyl sulfoxide nancy, 58 Vitamins
therapy, 560 propofol; aggressive sex behavior, 449 and minerals; dietary supplements, athletes, ergogen-
antiarrhythmic agents; side effects, 721 propranolol hydrochloride, comparison, enalapril ic effects, 900
anti-inflammatory agents; nonsteroidal, DUE criteria, maleate, hydrochlorothiazide; effects, cognition supplements; cystic fibrosis therapy, review, 657
780 and motor activity, quality of life, 300 vitamin A; mechanism of action, immunomodulating
antineoplastic agents; anemia, epoetin alfa therapy, quinacrine hydrochloride; side effects, pleurodesis so- effects, review, 506
DUE criteria, 925 lutions, 693 Volume of distribution, see Drugs, body distribution
asparaginase; pancreatitis, review, 440 replacement solutions; review, 335
atovaquone; side effects, 175; side effects, P. carinii sertraline hydrochloride; interactions, tranylcypro- Ww
pneumonia therapy, review, 563 mine, serotonergic syndrome, 222
azathioprine; pancreatitis, review, 440 sotalol hydrochloride; side effects, 883; side effects,
benzodiazepines; flumazenil-use criteria, 536; over- 176
dose, flumazenil therapy, overview, 691; overdose, strontium chloride Sr 89, 632 Warfarin
ccehlffpoirlrxeuaislmms aeiz;ho eynnd,dir ilaaf trleru;htme haaecz,ra earnpmciyiel,nt orgtorehneneivirdicaaeipwtzy,yo, ,l e46 l84a31tc ;kh ,e rr8ae7ps6yp ,i ra8t8o1 ry de- sssuuulllpfifyan,osd naaa1lc7ma;9iz idpneaesn;;c reapaagtnricatrinesua,lt oicrtyiestv,oi eswir,se ,v i4e4ws0, a rg44r0a mostim thera- Waramutsfyreaoi;rac lia enrvf daiilbaraunialtlt liiacoitonniafo,gna ;ru cclrtatiinhtoteenrsr;i; aa p,t yhw,3ea 0rr77af 2pa1yr ,in ;1 97D UE criteria, 307
ciprofloxacin; DUE criteria, 226 tacrine hydrochloride, 873 Weight; patients; effects, heparin dosage estimation, 597
ccilsaadprriibdien,e , 873961 ; side effects, leukemia therapy, review, tteetnriapcoyscildien;e s;s idpea necfrfeeacttist,i s6, review, 440 WoFmDeAn ; regcluilnaitciaoln s,s tu3d9i5e;s ; negwe ndderru-grse, laFtDedA driefgfuelraetnicoenss,,
805 thiazides; pancreatitis, review, 440 712
clonidine hydrochloride; side effects, lack, lactation, ticlopidine; DUE criteria, 64 Writing; review; drugs, articles, 306
infants, 178 ticlopidine hydrochloride; cholestasis, 398
cyclosporine; DUE criteria, transplant recipients, 696 tranylcypromine sulfate; interactions, sertraline, sero-
didanosine; pancreatitis, review, 440 ° tonergic syndrome, 222
didanosine, comparison, zalcitabine; side effects, valproic acid; pancreatitis, review, 440
AIDS therapy, NIAID clinical studies, 391 warfarin; DUE criteria, 307 Zalcitabine; comparison, didanosine; AIDS therapy, ef-
ddiiepcthiantrehyse, r siauc opmpablniednm aetnitteostn;a, n uesxH caeestmsooixpvoheii dlspu rso atnebdi nos,lp iegr9ot0su0sa scicsh arviadce- zzaollAcpIiitDdaSbe imnt eh,te arratpcryao,tme p; NarIiiAnssIooDnm ,nci lai ndiitcdahale nroasstpuyid,ni ee;rs ,e vis3ei9w1d, e 8e1f4f ects, Zobflioicnameco y,mm aaNbrI rAoIawrDi totcxrl;ia nnigscrpaallf atn sttvaustd.i ioehsno,,s t3 7931d6 i sease; prophylaxis,
conjugate vaccines; FDA approvals, marketing, 391 Tranquilizers; haloperidol lactate; aggressive sex be- Zolpidem tartrate; insomnia; therapy, review, 814
drugs; photosensitivity, review, 580 havior therapy, propofol toxicity, 449
enalapril maleate, comparison, hydrochlorothiazide, Transfection; gene therapy; research, review, 488
944 Clinical Pharmacy Vol 12 Dec 1993
Annual Index
Author Index Cheong, Ronnie Lum see Oparaoji, Edward C., 131 newborn twins, 615
Chin, Alfred see Okamoto, Mark P., 134 Greaney, James J. Jr. Ticlopidine-induced cholestatic
Chopineau, Jean Assay for midazolam in liquor folliculi jaundice (letter), 398
during in vitro fertilization under anesthesia, 770 Green, Laurence see Goldspiel, Barry R., 488
A Chow, Moses S. S. see Fan, Chengde, 917 Gregory, R. Elizabeth Paclitaxel: a new antineoplastic
Chow, Moses see also Kertland, Heather, 244 agent for refractory ovarian cancer, 401
Christensen, Michael L. Clearance of N-acetyl-i-ty-
Adamson, Robert T. Book review, 864 rosine in infants receiving a pediatric amino acid solu- H
Adir, Joseph S. see Oparaoji, Edward C., 131 tion, 606
Alaniz, Cesar Pharmacologic management of adult id- Cookson, Thomas L. see Ito, Matthew K., 126
iopathic nephrotic syndrome, 429 Cornish, Laura A. see Shaheen, Barbara E., 588
Allen, Jill E. Drug-induced photosensitivity, 580 Cornwell, Edward E. III see Oparaoji, Edward C., 131 Hale, Victoria G. Pharmacokinetics of oxaprozin (let-
Allen, Nancy M. Procainamide administration during Cété, Daniel Dosage of transdermal fentany] (letter), ter), 255
pregnancy, 58 718 Hall, Maura see Wallace, Carla S., 657
Alsop, Judith Book review, 627 Culbert, James P. see McCorvey, Eddie Jr., 300 Hall, Thomas G. Update on the medical treatment of
Anderson, John R. see Zeisler, John A. Jr., 527 Cziraky, Mark J. Low-molecular-weight heparins for hypercalcemia of malignancy, 117
Anderson, Philip O. Increasing breast milk supply the treatment of deep-vein thrombosis, 892 Hekmat, Elham see Oparaoji, Edward C., 131
(Therapy Consultation), 479 Helms, Richard A. see Christensen, Michael L., 606
AAnnndeetrts,s oMni,r iBaomr jeP . Ss.e es eeM cICpoporlviteiy,, CiEndddyi,e 5J2r.0, 300 D HHeermnianngd,e zD,e bJoerstaihs Ms.e e seDee aFmeerrn,a ndReozb erdte LG.a,t t3a8,0 Maria del
Artymowicz, Richard J. Atovaquone: a new antipneu- Mar, 515
mocystis agent, 563 Hess, David A. see Greaney, James J. Jr., 398
AAtteedssishhekkaaasddeii,, , 34AA rraassbb seHee liaclosob acBtoehr enpeykl,o ri Waayndn e peS.p,t i6c0 2 ulcer DDD’a’nAAzmmieaglteioro,,, SLLtaoeruvrieysn HFs..e es ePeFr roaWpsahegryn,l earGxii,ls l eBse writLti.lh, 4K8.a1 z Jt.r, e3o35n,a m4 15 plus HHioaettihte,nn tssJ, a anneJtda mCoerusitt peartDii.ae ntZfsoor,l pu3is0de7 e mo:f waa rfnaorinnb enizn oaddiualtz epiinpnae-
metronidazole during appendectomy (letter), 803 hypnotic for treatment of insomnia, 814
Davis, Sharon K. see Ninno, Mark A., 696 Hoffman, Elyse J. Flumazenil: a benzodiazepine antag-
Deamer, Robert L. Temafloxacin-induced hemolytic onist, 641
anemia and renal failure, 380 Holzinger, D. see Bunjes, R., 178
Deisseroth, Albert B. see Ippoliti, Cindy, 520 Hruska, Barbara M. see Good, Chester B., 780
Baltz, Julie K. Cladribine for the treatment of hemato- DeLisa, Anne F. see Gregory, R. Elizabeth, 401 Hsu, Van Doren Criteria for use of ticlopidine in adult
logic malignancies, 805 Deppe, Scott A. see Sargent, Andrea I., 613 inpatients and outpatients, 64
Bandettini, Francis C. see Bhatara, Vinod S., 222 DeVito, Joseph M. Bioequivalence of oral and injectable Hsu, Van Doren Use and safety of sumatriptan (letter),
Barron, Richard L. Criteria for use of aldesleukin in levoleucovorin and leucovorin, 293 258
adults, 853 DiPiro, Joseph T. Book review, 933
Barron, Richard L. Pathophysiology of septic shock and Doering, Paul L. see Beltz, Susan Durden, 900
implications for therapy, 829 Dole, Ernest J. Book review, 704
Bashaw, E. Dennis see Hale, Victoria G., 255 Dominguez-Gil Hurlé, Alfonso see Fernandez de Gat-
BBBaaeszdtiiinkd,ie a,Jn ,eP aineA-rnErntee ites neens eeCe hsOoepke iaCnmheooatupo,i, n eJaMeuaan,r, k J7e7Pa.0n, , 13747 0 DDroentayn,fe ulMsla-ryVi,ia g Aidlne,dl rMSeauwrs ,a nJ.5 1BD5o. o ks eer eIvtio,e wM, at2t41h ew K., 126 Ippmoalirtrio, w Citrnadnys plAadntv errsecei pieefnftesc,t s 52o0f molgramostim in
Beltz, Susan Durdan Efficacy of nutritional supple- Duc, Thomas A. see Michael, Katherine A., 150 Ito, Matthew K. Computer dosing program for the initi-
ments used by athletes, 900 Duren, Lars L. see Ito, Matthew K., 126 ation of vancomycin therapy, 126
Bennett, Teresa A. Criteria for use of epoetin alfa in
adult cancer and orthopedic-surgery patients, 925 E J
Berchou, Richard C. Book review, 242, 467
Berne, Thomas V. see Okamoto, Mark P., 134
BBhianlttkiranlaerte aiyoa,,nn dVJ oeintf nrfovardiens yyc leSrcF.a.y l pP Erofposfrsmeoicitbtnelse ie,n o fi 2mnh2at2eru rkmaeacrtnsi onai nl bbpueamttiwineen etnsa dmrsieecnretiirsav--- EEEznnegglellla,, n dJLeeiras,na n eFM r.a R.ns kese e eA R.o Mssaepreok neSdnh,,a laRPnaastykrliyec,ni ae StAM.e.,p, h6e516n70 J., 483 JJJJaaaafmnmfeneesys, ,,, CrRVLaaoiiubvgrei erenAtn.t EEs..se eeeIs I eIKeC hhsaAeonerpd tieDynremeiaoaamw,uei ,rc U,zjJ ,jea aRinonR,ibi ,ec 7rh7t7a0 7r 4dL . , J3.,8 05 63
ing parenteral nutrition, 377 Joch, Lois E. Accuracy of a first-order model for estimat-
Blanchard, Nick Book review, 787 F ing initial heparin dosage, 597
Bloom, Elana J. see Schwinghammer, Terry L., 736 Johnson, Curtis A. see Ateshkadi, Arasb, 34
Bobo, Don Jr. see Phelps, Stephanie J., 216 Johnson, Curtis A. see also Bohenek, Wayne S., 602
Boehm, Kristi A. see Christensen, Michael L., 606 Fallo, Sally A. see Min, David I., 610 Johnson, Jerry B. see DeVito, Joseph M., 293
BBoohh,e nLeakr,r y WEa.y sneee LSe.s tEifcfoe,c t Miotf chpeelrli toRn.i,t i5s7 1 on plasma and Fant,r atCihoen ndgedtee rmAicncautriaocny aofft eur nubloturanfdi-ltqruaitinoind,i n9e17 concen- JJouhnngsntiocnk,e l,P hilPaiupl E. WB.o okRe lraetviiveew , sa7f0e4t y and efficacy of
dialysate a,-acid glycoprotein concentrations in peri- Fernandez de Gatta, Maria del Mar Vancomycin phar- pravastatin (letter), 257
toneal dialysis patients, 602 macokinetics and dosage requirements in hematolog-
Borchardt-Phelps, Pamela K. Book review, 76 ic malignancies, 515
Bottorff, Michael see Joch, Lois E., 597 Fox, A. W. Use and safety of sumatriptan (letter), 258 K
Brosius, Frank C. III see Alaniz, Cesar, 429 Fraser, Gilles L. Vancomycin pharmacokinetics in eld-
Brown, Rex O. see Binkley, Jeffrey F., 377 erly patients (letter), 481
Brown, Rex O. see also Mowatt-Larssen, Christine A., Frisolone, Julie Criteria for use of intravenous cipro- Karnack, Charles M. Book review, 933
BBuurn2rj7,e6 s ,J. MRi. chCaloenli dsienee Reannfdr ob,r eWaisltl-ifaeme diHn.g, 2(3le2t ter), 178 Fruf5nl1so5,x acIignn afcoiro insfeeec tFioenrsn anind eazd ultd e pGaattitean,t s,M a2r2i6a del Mar, KKKaearswtlalogavunscdkh,y i,, H eRaYotobhseehrrit h iSAre.ol fs-esseet eu LdoUyme anieons,at treKroai,az lusyB eurnke iv,Mi .e,w7 ,66 89 234 4
Frye, Carla B. see Underwood, Theodore W., 440 Kessler, David A. mMepWatch: the new FDA medical
Cc Furmaga, Elaine M. Isolated systolic hypertension in products reporting program, 529
older patients, 347 Kessler, John M. Book review 934
Khanderia, Ujjaini Amiodarone-induced thyroid dys-
function, 774
Caballero, Dolores see Fernandez de Gatta, Maria del G Kienzle, Michael G. see Geraets, Douglas R., 721
Mar, 515 Kimelblatt, Bruce J. see Klausner, Mark A., 718
Calis, Karim Anton see Goldspiel, Barry R., 488 Klausner, Mark A. Dosage of transdermal fentany! (let-
CCaannsoancdoianay,t,e d MBiwrriuitcahe m pRrA.o. p Aosfmeooel r,oP uo4vs4l,9o wd,i siMnahtitbhiteewd Jb.,e h1a3 vior as- GGaalldeeissa,,r rhBMeaaarr rky( leJAt..t esreR)e,e cG8oa8gl1ne ist,i oMna rokf sAe.v,e r8e8 1 cefixime-induced KKoneutenprk)p,e, r 7,1C 8a Ntahnerciyn es eeA . Dseeaem eOrk,a moRotboe,r t MaL.r, k3 80P. , 134
Cantral, Kimberly A. see Jungnickel, Paul W., 257 Garnett, William R. Book review, 387 Koeppel, Robin M. see Zenk, Karin E., 846
Cantu, Thomas G. see Goemann, Marti, 802 Geraets, Douglas R. Atrial fibrillation and atrial flutter, Kozloski, Gary D. see DeVito, Joseph M., 293
CCaarrnttaeetrri,,o nBaBlaa rrrrhyyi gLhL. . bsCelueo rordael snopt r eFsruserumcraoegm amc,eo nmdmEailattitineoeen ,sM .,5 3of 3 4t7h e joint GGiilr7la2,l1 t ,M aSrekr giAo. sseeee OIpkpaomliottio, ,C iMndayr,k 5P2.0, 134 KKruedtonsrzkiea,ll )o,K ke,69 n1n Eedtwha rAd. sPe.e JuBdiinckiloeuys, Juesfef roefy fFl.,u m3a7z7e nil (edi-
Centers for Disease Control and Prevention Recom- Glowacki, Robert C. see Rospond, Raylene M., 179 Kuhn, Robert J. see Wallace, Carla S., 657
mendations of the Advisory Committee on Immuni-
zgaltoibounl inPsr actfiocr esp e(rAsCoInPs) : wiUtshe oafl tvearcecdi neism maunndo ciommmpuen-e GGoolteedmrs)ap, ni8en0l,2, MBaarrtriy RK.e tHoucmonaanz olgee nea ndth egraasptyr,i c 48a8c idity (let- L
tence, 675 Good, Chester B. Criteria for long-term use of nonste-
Champlin, Richard E. see Ippoliti, Cindy, 520 roidal anti-inflammatory drugs (NSAIDs) in adult in-
Chan, Frances A. see Sargent, Andrea I., 613 patients and outpatients, 780 Labreche, Dustan G. Book review, 706
Chandler, Mary H. H. see Rhoney, Denise H., 913 Goodin, Susan see Tsubaki, Tsuneo, 685 Lam, Nancy P. see Ateshkadi, Arasb, 34
Chandler, Mary H. H. see also Tsubaki, Tsuneo, 685 Gray, Thomas M. Gentamicin pharmacokinetics in term Lam, Y. W. Francis Fluorescence polarization immuno-
Chandler, Mary H. H. see also Welch, Laura P., 909
Vol 12 Dec 1993 Clinical Pharmacy 945
Annual Index
assay of quinidine, procainamide, and N-acetylpro- Pickworth, Kerry K. Long-term dobutamine therapy Theisen, Virginia see Khanderia, Ujjaini, 774
cainamide using Cobas-FP reagents, 49 (letter), 13 Tisdale, James E. see Fan, Chengde, 917
Lanao, José Martinez see Fernandez de Gatta, Maria del Poe, Timothy E. see Fox, A. W., 258 Tobert, Jonathan A. Relative safety and efficacy of
Mar, 515 Povilow, Matthew J. Long-term dobutamine therapy pravastatin (letter), 256
Leader, W. Greg see Rhoney, Denise H., 913 (letter), 13 Tolley, Elizabeth A. see Phelps, Stephanie J., 216
Leader, W. Greg see also Tsubaki, Tsuneo, 685 Powers, Douglas A. see Binkley, Jeffrey F., 377 Tonelli, Alfred P. see DeVito, Joseph M., 293
Leader, W. Greg see also Welch, Laura P., 909 Prichard, John G. see Deamer, Robert L., 380 Tsubaki, Tsuneo Estimation of creatinine clearance in
Lesar, Timothy S. see Lomaestro, Ben M., 693 Proctor, Jack D. see McCorvey, Eddie Jr., 300 patients with gynecologic cancer, 685
Lestico, Mitchell R. Polymyalgia rheumatica, 571 Przepiorka, Donna see Ippoliti, Cindy, 520
Leviton, Ira M. see Frisolone, Julie, 226 U
Lewis, Kelly S. see Michael, Katherine A., 150
Liem, Lorraine A. see Zenk, Karin E., 846
Lomaestro, Ben M. Pleurodesis with solution prepared
from quinacrine hydrochloride tablets, 693 Ueno, Kazuyuki Pharmacokinetics of mexiletine in
Lugo, Ralph A. Pathogenesis and treatment of bronchi- Raebel, Marsha A. Self-study material review, 548 middle-aged and elderly patients, 768
olitis, 95 Rawlings, D. Jim see Renfro, William H., 232 Ujhelyi, Michael R. see Fan, Chengde, 917
Lutomski, Dave M. see Joch, Lois E., 597 Reid, Dana J. Methotrexate for the treatment of chronic Umstead, Greg S. Self-study materials review, 243
corticosteroid-dependent asthma, 762 Underwood, Theodore W. Drug-induced pancreatitis,
Renfro, William H. Criteria for use of indomethacin 440
injection in neonates, 232
Rhoney, Denise H. Modified Michaelis-Menten equa- V
tion for estimating unbound-phenytoin concentra-
Mahoney, Charles D. see Greaney, James J. Jr., 398 tions, 913
Maiese, Susan see Ippoliti, Cindy, 520 Rogers, Susan J. Book review, 707
Mailliard, James A. see Rospond, Raylene M., 179 Rogers, Susan J. Pathophysiology and treatment of Valdés, Veronica see Anderson, Philip O., 479
Maloley, Pierre A. see Jungnickel, Paul W., 257 acute ischemic stroke, 359 Valley, Amy W. see Barron, Richard L., 853
Manzo, John see Frisolone, Julie, 226 Rospond, Raylene M. Dimethy! sulfoxide for treating Vaughan, Leigh M. Allergic bronchopulmonary as-
Marken, Patricia A. Criteria for use of lithium in adult anthracycline extravasation (Therapy Consultation), pergillosis, 24
inpatients and outpatients, 617 560 Veal, Donna F. see Christensen, Michael L., 606
McCorvey, Eddie Jr. Book review, 867 Rospond, Raylene M. Sargramostim for sulfasalazine-
McCorvey, Eddie Jr. Effect of hydrochlorothiazide, ena- induced agranulocytosis (letter), 179 Ww
lapril, and propranolol on quality of life and cognitive Rumore, Martha M. Vitamin A as an immunomodulat-
and motor function in hypertensive patients, 300 ing agent, 506
McKenney, James M. see McCorvey, Eddie Jr., 300
MMeiicshtaeerl,, FKraedt heLr. isneee ZAe.i slCerri,t erJioah n foAr. uJrs.e, 5o2f7 patient-con- S Wagernaetri,o nsB eritni l seKl.e cJt.i nPgh arcrmyasctoallloogiidc, aconldl oicdlailni,c ala ncdo nsoixdy--
trolled analgesia in adults, 150 gen-carrying resuscitation fluids, part 1, 335; part 2,
Miller, Jane L. Conference, reports address public- 415
health implications of tuberculosis (News), 167 San Miguel, Jestis F. see Fernandez de Gatta, Maria del Wallace, Carla S. Pharmacologic management of cystic
Miller, Jane L. Reviews of new drugs (editorial), 306 Mar, 515 fibrosis, 657
Miller, Lucinda G. Pharmacokinetics of oxaprozin (let- Sargent, Andrea I. Seizure associated with ondanse- Walton, Ted Felodipine and isradipine: New calcium-
ter), 256 tron, 613 channel-blocking agents for the treatment of hyper-
Min, David I. Encephalopathy associated with mu- Sautou, Valérie see Chopineau, Jean, 770 tension, 261
romonab-CD3, 610 Schaefer, C. see Bunjes, R., 178 Warren, Eric W. see Hoffman, Elyse J., 641
Mirtallo, Jay M. see Sunyecz, Lisa, 138 Schaiff, Robyn A. Burns see Hall, Thomas G., 117 Watkins, Cindy E. see Lam, Y. W. Francis, 49
Moline, Margaret L. Pharmacologic strategies for man- Schoeffler, Pierre see Chopineau, Jean, 770 Welch, Laura P. Predicting vancomycin pharmacokinet-
aging premenstrual syndrome, 181 Schumacher, Gerald E. Book review, 323 ics by using aminoglycoside pharmacokinetics, 909
Montello, Michael J. see Baltz, Julie K., 805 Schuna, Arthur A. see Lestico, Mitchell R., 571 Wheeler, Terrie see Good, Chester B., 780
Mowatt-Larssen, Christine A. Specialized nutritional Schwinghammer, Terry L. Pharmacologic prophylaxis Williams, Debra J. see Joch, Lois E., 597
support in respiratory disease, 276 of acute graft-versus-host disease after allogeneic Wingert, June see Bennett, Teresa A., 925
Murphy, Christine M. see Furmaga, Elaine M., 347 marrow transplantation, 736 Witmer, David R. Comment on ASHP therapeutic
Murray, Michael D. Book review, 866 Segars, Larry W. see Reid, Dana J., 762 guidelines (letter), 399
Shaheen, Barbara E. Magnesium in the treatment of Wittkowsky, Ann K. see Hiatt, Janet, 307
acute myocardial infarction, 588 Wojtysiak, Stacey L. see Binkley, Jeffrey F., 377
Shalansky, Stephen J. Effect of flumazenil on benzodi- Wood, Warren A. Comment on ASHP therapeutic
azepine-induced respiratory depression, 483 guidelines (letter), 399
Shepherd, Michele F. Bezoar formed by fragments of Wright, Jackson T. Jr. see McCorvey, Eddie Jr., 300
Nahata, Milap C. see Lugo, Ralph A., 95 extended-release nifedipine tablets, 849
Nakahiro, Randall K. see Okamoto, Mark P., 134 Shepherd, Michele F. Criteria for use of flumazenil in Y
Naumann, Terryn L. see Shalansky, Stephen J., 483 adult inpatients and outpatients, 536
Ninno, Mark A. Criteria for use of cyclosporine in adult Sherman, David G. see Rogers, Susan J., 359
transplant recipients, 696 Simonian, Jill S. see Ito, Matthew K., 126
Siram, Suryanarayana see Oparaoji, Edward C., 131 Yedinak, Kimberly C. Heparin and warfarin therapy
Oo SSkloivmsoewtiht,z , JoRni cRh.a rsde e BZoeoiksl err,e viJeowh,n 2A4.0 ,J r.8,6 45 27 Yelalfitne,r aAclubteer t myEo. csaere diOakla mointfoa,rc tiMoanr, k 19P7., 134
Smith, Steven P. Book review, 241
Smith, Terry see Ippoliti, Cindy, 520 Z
Okamoto, Mark P. Cefepime pharmacokinetics in pa- Spinler, Sarah A. see Cziraky, Mark J., 892
tients with acute cholecystitis undergoing cholecys- Spivey, J. Michael Criteria for use of ofloxacin and
Opatreacotjoim,y , Ed13w4a rd C. Aminoglycoside volume of distri- Sprlooamte,f lTohxaocmians inT .a dsuelet Yiendpiantaike,n tsK iamnbde rlouyt pCa.t,i e1n9t7s , 452 Zanetti, Leslie A. Farquhar Sotalol: a new class III anti-
bution in postoperative patients with septic shock, Steiner, Joseph F. Finasteride: a 5a-reductase inhibitor, arrhythmic agent, 883
131 15 Zeisler, John A. Jr. Lidocaine therapy: time for re-evalu-
Orlando, Patricia L. Book review, 82 Storm, Michael C. see Christensen, Michael L., 606 ation, 527
Oxton, Lisa L. see Bohenek, Wayne S., 602 Sunyecz, Lisa Sodium imbalance in a patient receiving Zellmer, William A. Context of a transition (editorial),
total parenteral nutrition, 138 923
P Symes, Laura R. see Walton, Ted, 261 Zenk, Karin E. Comparative efficacy of glycerin enemas
and suppository chips in neonates, 846
Zimmerman, Stephen W. see Bohenek, Wayne S., 602
T
Page, Richard L. see Allen, Nancy M., 58
Palmieri, James see Alaniz, Cesar, 429
Perry, Paul J. see Hoehns, James D., 814 Taketomo, Carol K. Book review, 787
Phelps, Stephanie J. Infusion technology for predicting Talley, C. Richard The new AJHP (editorial), 526
and detecting infiltration of peripheral intravenous Tanaka, Kazuhiko see Ueno, Kazuyuki, 768
catheter sites in infants, 216 Terrisse, Marie-Pierre see Chopineau, Jean, 770
946 Clinical Pharmacy Vol 12 Dec 1993